IVW-CLR-CS27- 400 ivWatch SmartTouch Sensor:  
Device Validation  for Infiltrated Tissues  
 
CONFIDENTIAL  1 of 58 
 
 
 
 Clinical Investigational Plan 
 
ivWatch SmartTouch Sensor: 
Device Validation for Infiltrated Tissues   
 
 
William J. Naramore  
Susan Brown, MSN, MSED, BA , VA-BC 
Gregory J. Schears, M.D.  
Marisa A. Cole 
  
 
ivWatch, LLC  
469 McLaws Circle 
Williamsburg, VA 23185  
 Version  Date: March 12 , 2019  
 
Clinica lTrials.gov Study ID: [REMOVED] 
  

IVW-CLR-CS27- 400 ivWatch SmartTouch Sensor:  
Device Validation  for Infiltrated Tissues  
 
CONFIDENTIAL  2 of 58 
Table of Contents  
General Information ..................................................................................................... 5 
Rationale and Background .......................................................................................... 6 
ivWatch Model 400 Clinical Studies  ...................................................................................... 8  
ivWa tch SmartTouch Sensor Clinical Study Plan  ................................................................. 9  
Infiltration Detection by the Perfect Clinician  ................................................................... 10 
Study Goals and Objectives ...................................................................................... 18 
Study Design ................................................................................................................ 18 
Methodology ............................................................................................................... 23 
Subject Recruitment  .............................................................................................................. 23 
Preliminary Information and Consent ................................................................................. 24 
Data Collection  ...................................................................................................................... 25 
Subject Preparation  ............................................................................................................... 25 
Data Collection  ...................................................................................................................... 26 
End of Study ............................................................................................................................. 26 
Data Analysis  ......................................................................................................................... 27 
Risk Benefit Analysis .................................................................................................... 27 
Injection of Isotonic Saline  ................................................................................................... 27 
The ivWatch Technology  ...................................................................................................... 28 
Follow-Up ..................................................................................................................... 30 
Data Management and Statistical Considerations ................................................. 30 
Data Management  ................................................................................................................ 30 
Statistical Considerations ...................................................................................................... 31 
Primary Objective  ................................................................................................................... 31 
Secondary Objectives  ........................................................................................................... 33 
Quality Assurance ....................................................................................................... 35 
Monitoring Plan ........................................................................................................... 35 
Expected Outcomes of the Study ............................................................................. 36 
Publication Policy........................................................................................................ 36 
Duration of the Study .................................................................................................. 36 
Anticipated Problems ................................................................................................. 36 
Ethics ............................................................................................................................ 36 
Good Clinical Practice ............................................................................................... 36 
IVW-CLR-CS27- 400 ivWatch SmartTouch Sensor:  
Device Validation  for Infiltrated Tissues  
 
CONFIDENTIAL  3 of 58 
Clinical Trial Insurance ............................................................................................... 37 
Informed Consent Forms ............................................................................................ 37 
Deviations from the Protocol ...................................................................................... 37 
Serious Adverse Events / Device Deficiencies ......................................................... 37 
Case Report Form ....................................................................................................... 38 
Pre-Screening Form .................................................................................................... 41 
Health History Form ..................................................................................................... 43 
Skin Pigmentation Worksheet .................................................................................... 44 
Pre-Study Checklist ..................................................................................................... 46 
Data Collection Checklist .......................................................................................... 47 
FDA Clearance Letters for ivWatch Model 400 ........................................................ 51 
Investigator Signatures ............................................................................................... 55 
Statistical Monte Carlo Analysis ................................................................................ 56 
Bibliography ................................................................................................................ 58 
  
Figures 
Figure 1. ivWatch Model 400 Infiltration Monitoring System ...................................................................  7 
Figure 2. ivWatch Model 400 with Extension Module and SmartTouch Sensor  .................................... 8  
Figure 3. The sensitivity of a perfect clinician for identifying early infiltrations (infiltrated volume < 
10mL).  ............................................................................................................................................................  11 
Figure 3. Pre -study measurements performed on each subject.  ........................................................  19 
Figure 5. The four possible anatomical sites monitored during this study.  .......................................... 19 
Figure 6. The Sonosite S -Serie s commercial ultrasound imaging system.  ...........................................  21 
Figure 7. Example of the ivWatch SmartTouch sensor  ...........................................................................  22 
Figure 8. The ivWatch Patient Monitor with extension module and user interface elements.  ........ 23 
Figure 9. The Monte Carlo simulation of a device operating with an infiltration sensitivity equivalent to the perfect clinician (null hypothesis) and a device operating at a 90% sensitivity (alternative hypothesis). The red line shows the location of Î±=0.041 threshold (one- sided).  ...............................  32
 
Figure 10. The statistical power for a 98 PIV site study as a func tion of the device sensitivity (specific 
alternative hypothesis).  .............................................................................................................................. 33 
Figure 11. Statistical power vs sample size for detection volume c omparison  ..................................  34 
Figure 12. Examples of confidence intervals at various ST sensitivities, assuming FO sensitivity = 96%. ........................................................................................................................................................................ 35
 
 
IVW-CLR-CS27- 400 ivWatch SmartTouch Sensor:  
Device Validation  for Infiltrated Tissues  
 
CONFIDENTIAL  4 of 58 
 
Tables 
Table 1. The recommended site assessment frequency by the Infusion Nurses Society.  ................  11 
Table 2. Clinical studies performed with the ivWatch Model 400 device.  .........................................  12 
Table 3. Clinical studies performed with SmartTouch sensor.  ...............................................................  15 
Table 4. The study configuration.  ..............................................................................................................  20 
Table 5. List of study exclusion criteria.  .....................................................................................................  24 
Table 6. Clinical trials involving the ivWatch technology.  .....................................................................  29 
Table 7. The study configuration for the infiltration study ...................................................................... 31 
 Project Summary  
Peripheral intravenous (PIV) therapy is one of the most common invasive procedures performed 
in US hospitals. PIV failures often occur when fluids leak out of the vein into surrounding tissue. This failure is called an infiltration for the leakage of non -vesicant solutions or an extravasation for 
vesicant solutions. The ivWatch Model 400 is a device that assists medical professionals in monitoring patients for PIV infiltration and extravasation events using an optical sensor. This device received FDA clearance for use in the adult and pediatric age groups in February 2015 and December 2016, respectively. The corresponding FDA letters are included on Page 51.  
ivWatch is enhancing the Model 400 to support a new disposable electronic sensor, called SmartTouch. In this study, the SmartTouch sensor cable will be tested to show equivalence to the original Model 400 fiber optic sensor. The new sensor design includes optical components in the 
sensor package, similar to a typical pulse oximeter. This design allows the sensor to be lower cost and disposable. The goal of this study is to validate the performance of the ivWatch SmartTouch 
sensor  for detecting the early st ages of an IV infiltration, as collected from healthy adult 
volunteers. The Model 400 Fiber Optic sensor is used for performance comparison.  
The study objectives include:  
Primary Objective : Demonstrate a statistically significant improvement for detecting  early stage 
infiltrations in comparison to hourly observation by a perfect clinician.  
Secondary Objectives : 
1. Demonstrate statistical equivalence in infiltration detection volume of the SmartTouch and Fiber Optic sensors.  
2. Demonstrate statistical equivalence  in infiltration sensitivity of the SmartTouch and Fiber 
Optic sensors.  
 
 
IVW-CLR-CS27- 400 ivWatch SmartTouch Sensor:  
Device Validation  for Infiltrated Tissues  
 
CONFIDENTIAL  5 of 58 
General Information 
Protocol Title:  
ivWatch SmartTouch Sensor: Device Verification for Infiltrated Tissues   
Name and Address of Sponsor: 
Corporate Location  
ivWatch, LLC  
 1100 Explor ation Way  
Suite 209  
 Hampton, VA 23666 
 1.855.489.2824  
  
 Research and Development Location  
ivWatch, LLC  
 469 McLaws Circle 
 Williamsburg, VA 23185  
 1.855.489.2824  
 Name and Title of Investigators:  
William J. Naramore, Chief Technology Officer, Principal  Investigator  
Susan Brown, MSN, MSED, BA , VA-BC, Chief Nursing Officer  
Gregory J. Schears, M.D., Consultant serving as Chief Clinical Officer  
Marisa A. Cole, Biomedical Engineer  
All investigators work at ivWatch, LLC and have the following address and phone number. The 
clinical study will take place at this location.  
Research and Development Location  
ivWatch, LLC  
 469 McLaws Circle 
 Williamsburg, VA 23185  
 1.855.489.2824  
 
 
  
IVW-CLR-CS27- 400 ivWatch SmartTouch Sensor:  
Device Validation  for Infiltrated Tissues  
 
CONFIDENTIAL  6 of 58 
Rationale and Background 
Peripheral intravenous (PIV) therapy is one of the most common invasive procedures performed 
in US hospitals. Over 25 million patients, or approximately 80% of hospital patients, require intravenous  therapy each year in the United  States  [1]. Despite wides pread use, a number of 
potential complications can occur during PIV therapy.  Infiltration is the most common mode of PIV catheter failure, with an average incidence rate of 23.9% according to a prospective randomized review of controlled studies from 1999 to 2014 [2]. The other common modes of failure 
are catheter occlusion / mechanical failure (18.8%), catheter -related phlebitis (15,4%), catheter 
dislodgement (6.9%), and catheter -related infection (0.2%) [2]. A multicenter trial indicated 
infiltrations oc curred 27 -32 times per 1000 intravenous catheter days in adults  [3].  Infiltration is the 
leakage of non -vesicant fluids like saline into the surrounding tissue. Extravasation is the leakage 
of vesicant fluids, which include cytotoxic drugs, intraveno us nu trition, and calcium, potassium, 
and bicarbonate solutions [4].  
IV infiltration or extravasation is usually accompanied by pain, erythema, and/or edema in the vicinity of the insertion site. Severe infiltration and extravasation may lead to necrosis requiring skin debridement, skin grafting, or amputation  [5].
 One common area of malpractice lawsuits filed 
against physicians and nurses involves infiltration or extravasation  [6]. It has been reported that 
the infiltration rate for contrast media injections i s independent of infusion rate and it does not vary 
significantly with regard to injection site, catheter size, or catheter type  [7]. A randomized 
controlled trial including 3,283 adult medical and surgical patients with 5,907 total catheters indicated tha t PIV catheter occlusion rate (including infiltration) is improved by forearm insertion 
versus hand, antecubital fossa, or upper arm [8]. T he reported incidence of infiltration in the 
neonatal intensive care unit (NICU) population is between 23% and 78% an d carries the potential 
for long- term sequelae [9] .  
ivWatch, LLC has developed the ivWatch Model 400 â€“ a Class II medical device that is cleared for 
use on adults and pediatrics. The ivWatch Model 400 is indicated for the detection of subcutaneous infiltrations and extravasations of 10 cc or less of optically clear infusates, as an adjunctive device to the clinical evaluation in the healthcare setting of adults and pediatrics with PIVs.  
The ivWatch Model 400 consists of the ivWatch Patient Monitor (IPM), reusable fiber optic sensor cable, and sensor cable receptacle. As illustrated in Figure 1 below, the reusable fiber op tic sensor 
delivers visible and near -infrared  light to the ti ssue and transmits reflected light back to the IPM.  
The IPM contains an optical system that generates light signals that are sent to the patientâ€™s skin (via the reusable fiber optic sensor cable), and measures the light returning from the patientâ€™s skin (also via the reusable fiber optic sensor cable).  The sensor head of the reusable fiber optic sensor 
cable is held in place and attached to the patient using the sensor receptacle. The IPM also contains the hardware for executing the proprietary ivWatch signal processing algorithm, and for displaying system status on a user interface, including audible and visual notifications indicating changes to the state of the PIV.  
When changes in the diffuse reflectance in the tissue near the peripheral IV insertion si te are 
consistent with an infusate pooling in the subcutaneous tissue, the IPM emits audible and visual 
IVW-CLR-CS27- 400 ivWatch SmartTouch Sensor:  
Device Validation  for Infiltrated Tissues  
 
CONFIDENTIAL  7 of 58 
notifications intended to prompt the clinician to inspect the peripheral IV site for a possible 
infiltration event.  Prompt identification of infiltrations reduces the risk of injury to patients undergoing peripheral IV therapy and improves the likelihood of receiving the correct dosage of medications delivered intravenously.  
 
Figure 1. ivWatch Model 400 Infiltration Monitoring System  
The ivWatch Model 400 system has been expanded to support both the fiber optic sensor cable configuration of the existing Model 400 as well as an electronic sensor cable configuration (SmartTouch). The SmartTouch sensor consists of low -cost optical components built into the sensor 
head, like disposable pulse oximeter sensors. This design allows the SmartTouch sensor to be a more cost effective single -use sensor, as opposed to the costlier reusable fiber optic sensor. An 
extension module compatible wi th the existing ivWatch Model 400 was developed to support an 
electronic sensor cable configuration, (Figure 2). The Extension Module is connected to the IPM via USB. The SmartTouch sensor was designed to be an electronic version of the Model 400 fiber 
optic sensor. The sensor is placed on the skin of a patient near the PIV site, following the protocol 
as the Model 400, and the same indications for use apply.  

IVW-CLR-CS27- 400 ivWatch SmartTouch Sensor:  
Device Validation  for Infiltrated Tissues  
 
CONFIDENTIAL  8 of 58 
 
Figure 2. ivWatch Model 400 with Extension Module and SmartTouch Sensor  
ivWatch Model 400 Clinical Studies  
The ivWatch Model 400 was tested in a series of IRB -approved studies on healthy adult research 
subjects, as summarized in Table 2. The Design Verification studies evaluated the performance of 
the device under different co nditions. The NIR Detection of PIV Infiltration study evaluated two 
models of PIV infiltration as well as potential algorithm correction for changes in tissue blood 
volume. The Signal Variation of Normal Tissue study evaluated the sources and rates of non -
infiltration alarms when monitoring normal, non -infiltrated tissues. In this protocol document, the 
terms â€˜alarmâ€™ and â€˜notificationâ€™ are considered interchangeable. Two clinical studies evaluated how the infiltration rate and catheter depth affected the di agnostic performance of the ivWatch 
Model 400. The device detected all 10mL infiltrations for common adult infusion rates ranging from 5 mL/hr to 150 mL/hr. The device detected all infiltrations with a catheter depth less than 5 mm deep although deeper inf iltrations caused a reduced sensitivity by the device. The final study 
assessed the adhesion of the ivWatch receptacle over a 96 hour period. There were no adhesion issues with the receptacle when used with an occlusive dressing.  
After completing the desig n verification studies, two additional studies were performed to validate 
the final design. The study, titled Device Validation for Non -Infiltrated Tissues, evaluated non -
infiltrated sites over a 24 hour period. The device issued a false red notification once every 4.2 days and a false yellow notification once every 2.0 days. These notifications were often caused by compression of the IV site. The next study, titled Device Validation for Infiltrated Tissues, evaluated the performance of the ivWatch Model 400 for detecting 140 infiltrated IV sites. Of the 140 IV sites, the ivWatch device issued 135 red notifications (96% sensitivity) and 139 yellow notifications (99% sensitivity). These results demonstrated the ivWatch Model 400 is highly sensitive 

IVW-CLR-CS27- 400 ivWatch SmartTouch Sensor:  
Device Validation  for Infiltrated Tissues  
 
CONFIDENTIAL  9 of 58 
to infiltr ated PIV sites on the hands and forearms of adults while having a false notification rate 
that should have negligible effects on clinical alarm fatigue.  
Three additional IRB -approved studies were performed to (1) examine the infiltration detection 
performa nce as a function of the distance separating the catheter tip and ivWatch sensor, (2) 
examine the infiltration detection performance when the sensor is placed above and below a 
transparent occlusive dressing, and (3) examine the false notification rate when the sensor is placed above a transparent occlusive dressing.  
After the FDA clearance for ages 18 and up, an IRB -approved clinical study was conducted to 
measure the performance of the ivWatch Model 400 device for detecting early stage infiltrations on pediatric patients at Cincinnati Childrenâ€™s Hospital Medical Center. Hospitalized pediatric patients under the age of 18 who received continuous IV therapy were monitored with the device. The study was broken into two groups, 156 subjects in a blinded non -alarming group, and 57 
subjects in an alarming group. The objectives of the study were to determine the amount of time between infiltration detection by the clinician and the device as well as the device sensitivity and specificity. Each site was continuousl y monitored during IV therapy and the IV was terminated if 
an infiltration was detected or other complications were identified. In the nonalarming group, the device issued red â€œCheck IVâ€ notifications a median time of 15.2 hours before clinician detection.  
The device issued notifications for 18 out of 23 clinician -confirmed infiltrations in the non -alarming 
group, for a sensitivity of 78.3%. In the alarming group, the device issued notifications for 12 out of 15 clinician -confirmed infiltrations. The result s from this study were used to support the FDA 
clearance for all age groups including pediatrics in December of 2016.  
ivWatch SmartTouch Sensor Clinical Study Plan  
A series of new clinical studies are taking  place to test  feasibility  as well as to  verify and validate 
the SmartTouch sensor in a similar way to the Model 400.  Two feasibility studies were  completed 
to examine  the â€˜alphaâ€™ design of the SmartTouch sensor in terms of  (1) infiltration signal 
performance and (2) false notification rate of the Smar tTouch sensor  (Table 3). These studies have 
indicated the optical design of the alpha SmartTouch sensor performs equivalently to the Model 
400 fiber optic sensor.  Four verification  studies were  performed to test the â€˜betaâ€™  SmartTouch 
design and show equiva lence to the Model 400 in terms of (1) device sensitivity and (2) false 
notification rate.  The beta SmartTouch design contains the same optical sensor as alpha, but 
improvements were  made to the sensor for increased durability  and manufacturability . Signal  
data from the se verification studies may be used to improve signal processing algorithms prior to 
final software design.   
This clinical protocol is the validation study that will examine the infiltration sensitivity performance 
of the ivWatch SmartTouch sensor versus the Model 400 fiber optic sensor. This study is modeled 
after the clinical protocol used to validate the Model 400 system, Device Validation for Infiltrated Tissues (Table 2). The primary objective of the study is to demonstrate a statistical ly significant 
improvement for detecting early stage infiltrations in comparison to hourly observation by a perfect clinician , the current clinical standard . The secondary objectives are to demonstrate 
statistical equivalence in (1) infiltration detection volume and (2) infiltration sensitivity of the SmartTouch and Fiber Optic sensors.  
IVW-CLR-CS27- 400 ivWatch SmartTouch Sensor:  
Device Validation  for Infiltrated Tissues  
 
CONFIDENTIAL  10 of 58 
Infiltration Detection by the Perfect Clinician  
To be an effective product, the ivWatch sensors must detect early stage infiltrations significantly 
better than the current n ursing standard of care. To facilitate this comparison and provide 
conservative estimates of the device performance, the idea of a perfect clinician is used, that is, a clinician who assesses the IV site hourly and perfectly classifies the IV site as norma l or infiltrated, 
regardless of how much fluid has been infiltrated into the tissue.  
The primary metric used to compare the performance of the ivWatch device with the perfect clinician is the early infiltration sensitivity. The infiltration sensitivity is the percentage of early stage 
infiltrations (<10mL) detected by the ivWatch device or the perfect clinician. For the ivWatch device, the infiltration sensitivity is the ratio of the sites that generate a red alarm to the total number of monitored sites. For the perfect clinician, the infiltration has the same probability of occurring at any time between clinical assessments. Consequently, the percentage of infiltrations detected by the perfect clinician prior to 10mL of infiltrated volume is given by  
S
ð¶ð¶= min ( 100% ,ð‘‰ð‘‰ð‘™ð‘™ð‘™ð‘™ð‘™ð‘™
ð‘…ð‘…âˆ™ð‘‡ð‘‡ð¶ð¶âˆ—100% ) 
where V lim (mL) is the 10mL volume limit, R (mL/hr) is the infiltration rate, and T C is the observation 
period (hr). For example, at 100 mL/hr (R=100), the perfect clinician making hourly assessments (T
C=1) of the site would be expected to detect 10% ( Clinician Sensitivity = SC) of the infiltrations 
prior to 10mL (V lim=10).  
Figure 3 illustrates the infiltration sensitivity of a perfect clinician for different infiltration rates and 
observation periods. A highlighted box indicates common adult infusion rates. The performance of the perfect clinician is limited by how frequently the site can be assessed. If the perfect clinician could monit or the site continuously (observation period = 0), the clinicianâ€™s infiltration sensitivity 
would be perfect.  
IVW-CLR-CS27- 400 ivWatch SmartTouch Sensor:  
Device Validation  for Infiltrated Tissues  
 
CONFIDENTIAL  11 of 58 
 
Figure 3. The sensitivity of a perfect clinician for identifying early infiltrations (infiltrated volume < 
10mL).  
The f requency of IV site assessments can vary significantly in practice depending on the clinicianâ€™s 
workload and the perceived risks to the patient. Table 1 includes the assessment frequency 
recommended in a position paper published by the Infusion Nurses Society  [10]. Discussions with 
clinicians suggest most peripheral IV sites are checked either once per hour or less frequently. As 
described later, the primary statistica l objective in this validation study was performed assuming 
hourly observation by a perfect clinician.  
Table 1. The recommended site assessment frequency by the Infusion Nurses Society.  
Assessment Frequency  Description  
At least every 4 hours  â€¢ Patients who are receiving nonirritant/nonvesicant 
infusions and who are alert and oriented and who are 
able to notify the nurse of any signs of problems such as 
pain, swelling, or redness at the site.  
At least every 1 to 2 hours  â€¢ Critically ill patients  
â€¢ Adult patients who have cognitive/sensory deficits or 
who are receiving sedative- type medications and are 
unable to notify the nurse of any symptoms  
â€¢ Catheters placed in a high- risk location ( e.g., external 
jugular, area of flexion)  
At least every hour  â€¢ Neonatal patients  
â€¢ Pediatric patients  
More frequently (every 5 
to 10 minutes)  â€¢ Patients receiving intermittent infusions of vesicants  
 
 

IVW-CLR-CS27- 400 ivWatch SmartTouch Sensor:  
Device Validation  for Infiltrated Tissues  
 
CONFIDENTIAL  12 of 58 
Table 2. Clinical studies performed with the ivWatch Model 400 device.  
Study  Purpose  Outcome  Key Performance Metrics  
NIR Detection of PIV 
Infiltration  
ivWatch Study ID:  IVWRSCS- 01 
Chesapeake IRB ID:  00008513 
Number of Subjects:  24 
Number of Sites:  48 
Dates:  June- August 2013  
 1. Investigate in vivo  model of 
subcutaneous injections near 
vascular bundles as substitute to through vein infiltrations.  
2. Validate sensor and receptacle designs.  
3. Investigate and validate effect of tissue blood volume changes on 
signal.  â€¢ Subcutaneous injections are 
more challenging to detect.  
â€¢ Validated the sensor and receptacle designs.  
â€¢ Insensitive to changes in the tissue blood volume.  
 Diagnostic Performance  
(all, subcutaneous, through -vein):  
â€¢ Sensitivity: 90%, 83%, 96%  
â€¢ Specificity: 100%, 100%, 100%  
Detected Volume â€¢ Through -Vein: 2.0mL  
â€¢ Subcutaneous: 3.3mL  
The Signal Variation of 
Normal Tissue  
ivWatch Study ID:  IVW400CS -
01 
Chesapeake IRB ID:  00008218 
Number of Subjects:  30 
Number of Sites:  30 
Dates:  August -November 2013  1. Identify sources of non -infiltration 
alarms.  
2. Estimate rates of non -infiltration 
alarms for patients in an environment 
that mimics a hospital room.  
3. Investigate potential interference 
between other near infrared devices.  â€¢ Negligible impact on clinical 
alarm fatigue.  
â€¢ Non-infiltration alarms 
generated by tissue 
deformation.  
â€¢ No infiltration alarms due to 
device interference.  Red Alarm Rate:   
â€¢ 0.11 red alarms / day  
â€¢ 3 alarms in 661 hours  
Yellow Alarm Rate:  
â€¢ 0.40 yellow alarms / day 
â€¢ 11 alarms in 661 hours  
The Effect of Catheter 
Depth  
ivWatch Study ID:  IVW400CS -
02 
Chesapeake IRB ID:  00008254 
Number of Subjects:  28 
Number of Sites:  56 
Dates:  September -October 
2013 1. Determine relationship between 
infiltration depth and ivWatch sensitivity.  
2. Investigate tissue characteristics that affect ivWatch performance.  â€¢ Validation of optical modeling.  
â€¢ ivWatch sensitivity greatest for infiltration depths < 5mm.  
â€¢ Presence of a fascia interposed between catheter tip and sensor reduces sensitivity.  Depths Less than 5mm (On -
Design) 
â€¢ 1-3mm Deep: 100% sensitive 
(12/12)  
â€¢ 3-5mm Deep:  100% sensitive 
(17/17)  
Depths Greater than 5mm (Off-Design): 
â€¢ 5-7mm Deep:  38% sensitive (5/13)  
â€¢ 7-9mm Deep:  50% sensitive (7/14)  
 
The Effect of Infiltration Rate  
ivWatch Study ID:  IVW400CS -
03 Chesapeake IRB ID:  00008941 
Number of Subjects:  24 
Number of Sites:  48 
Dates:  October -November 
2013 1. Determine volumes of infiltration fluid 
required to generate alarm as a function of infiltration flow rate.  
2. Determine times required to 
generate an alarm as a function of 
infiltration flow rate.  â€¢ Detected all infiltrat ions 
regardless of infiltration rate.  
â€¢ The response time of the system strongly determines the 
detected volume when the 
device alarms.  Sensitivity & Median Detected 
Volume 
â€¢ 5mL/hr:  100% (12/12) and 0.9mL  
â€¢ 50mL/hr:  100% (12/12) and 2.2mL  
â€¢ 100mL/hr:  100% (12/12) and 3.7mL  
â€¢ 150mL/hr:  100% (12/12)  and 5.7mL  
IVW-CLR-CS27- 400 ivWatch SmartTouch Sensor:  
Device Validation  for Infiltrated Tissues  
 
CONFIDENTIAL  13 of 58 
Long Term Adhesion of the 
ivWatch Receptacle  
ivWatch Study ID:  IVW400CS -
04 
Chesapeake IRB ID:  00008891 
Number of Subjects:  6 
Number of Sites:  18 
Dates:  October 2013  1. Evaluate ability of receptacle to  
remain adhered to skin over 96-hour 
period.  
2. Evaluate skin integrity after receptacle was adhered for 96 hours.  
3. Identify activities that may degrade adhesion of receptacle to the skin.  â€¢ ivWatch receptacles remained 
adhered to skin for 96 hours when combined  with occlusive 
dressing.  
â€¢ The ivWatch receptacle did not cause significant disruption to skin integrity after 96 hours.  Average Adhesion Time  
â€¢ Receptacle Only:  
   68 hrs (6 sites)  
â€¢ Receptacle & Dressing:  
    96 hrs (6 sites)  
â€¢ Receptacle, Dressing, Sensor:  
    96 hrs (6 sites)  
Device Validation for Non -
Infiltrated Tissues   
ivWatch Study ID:  IVW400CS -
05 
Chesapeake IRB ID:  00009175 
Number of Subjects:  40 
Number of Sites:  40 
Dates:  January 2014  
 1. Validation trial measuring safety and 
efficacy of final Model 400 device 
when monitoring non -infiltrated 
tissues.  
2. Estimate rates of non -infiltration 
alarms for active patients in a hospital room environment.  
3. Demonstrate performance in the presence of interference sources.  â€¢ Device can monitor normal 
tissue with minimal impact on clinical alarm fatigue.  
â€¢ The device can be used without skin irritation or 
disruption to the skin integrity.  
â€¢ The device operates properly in 
cases of interference by other light sources.
 Red Alarm Rate:   
â€¢ 0.24 red alarms / day 
â€¢ 1 red alarm every 4.2 days  
â€¢ 9 alarms in 900 hours  
 
Yellow-Only Alarm Rate:  
â€¢ 0.51 yellow alarms / day 
â€¢ 1 yellow alarm every 2.0 days  
19 alarms in 900 hours  
Device Validation for 
Infiltrated Tissues   
ivWatch Study ID: IVW400CS -
06 Chesapeake IRB ID:  00009285 
Number of Subjects:  70 
Number of Sites:  140 
Dates:  February 2014  1. Validation trial measuring safety and 
efficacy of final Model 400 device when monitoring infiltrated tissues.  
2. Estimate sensitivities of device for detecting early-stage infiltrations (< 10mL infiltrated fluid).  
3. Demonstrate significant improvement compared to routine observation by a perfect clinician.  â€¢ Detected vast majority of 
infiltrations regardless of infiltration rate, PIV location, 
skin pigmentation, or body 
type.  
â€¢ Significant improvement 
compared to the current standard â€“ routine observation 
by a nurse. 
â€¢ No safety concerns were 
observed â€“ no skin irritation or 
disruption to skin integrity  Red Alarm Sensitivity :  
â€¢ 96.4% Sensitivity  
â€¢ Red Alar m on 135 out of 140 
cases  
â€¢ 91.4 to 98.7% for 95% Conf. Interval  
 
Yellow Alarm Sensitivity:  
â€¢ 99.3% Sensitivity  
â€¢ Yellow Alarm on 139 out of 140 cases  
95.5 to 99.96% for 95% Conf. 
Interval  
The Effect of Sensor -to-
Catheter Distance  
ivWatch Study ID:   
IVW-CLR-CS12- 400 
Chesapeake IRB ID : 00010217 
Number of Subjects:  23 
Number of Sites:  46 
Dates : November 2014  1. Quantify the sensitivity of the 
ivWatch device for each catheter-to-sensor distance.  
2. Estimate the detected volume for the yellow and red notificati ons of 
the ivWatch device as a function of catheter -to-sensor distance.  â€¢ The device detected most 
infiltrations although the detected volume increased for larger sensor- to-catheter 
separations 
â€¢ The device sensitivity decreases with larger separations consist ent with the hypothesis 
that the infiltration does not 
always diffuse uniformly.  Sensitivity:  
â€¢ 100% for 10 &  20mm  separations  
â€¢ 90% for 30mm separation  
â€¢ 89% for 40mm separation  
â€¢ 78% for 50mm separation  
Detected Volume (Median): â€¢ 2.8, 7.7, 12.3, 21.7, 32.8 mL for  10, 20, 30, 40, 50mm separations, respectively.  
IVW-CLR-CS27- 400 ivWatch SmartTouch Sensor:  
Device Validation  for Infiltrated Tissues  
 
CONFIDENTIAL  14 of 58 
Infiltration Detection when 
Placing Over the Dressing 
ivWatch Study ID:   
IVW-CLR-CS15- 400 
Chesapeake IRB ID : 00013715 
Number of Subjects:  24 
Number of Sites:  48 
Dates : Octo ber 2015  1. Estimate the difference in 
detected volume when placing 
above and below dressing.  
2. Demonstrate statistically significant improvement for detecting early stage infiltrations in comparison to hourly observations by a perfect clinician.  â€¢ The device detected most 
infiltrations with no statistically significant difference in sensitivities for over or under the dressing.  
â€¢ No statistically significant difference between detected volumes for over or under the 
dressing.  Sensitivity:  
â€¢ 100% (24/24)  for under the 
dressing  
â€¢ 95.8% (23/24) for over the dressing  
Detected Volume (Mean): â€¢ 2.93 and 2.75 mL for under and over the dressing, respectively.  
 
Performance for Non -
Infiltrated Tissues when 
Placing Over Transparent 
Occlusive Dressing  
ivWatch Study ID:   
IVW-CLR-CS16- 400 
Chesapeake IRB ID : 00015068 
Number of Subjects:  25 
Number of Sites:  25 
Dates : April -June 2016  1. Estimate the non -infiltration red and 
yellow notification rates for the 
ivWatch device.  
2. Determine whether the over- the-
dressing red notification rate is 
significantly less than 1 false red 
notification per day.  â€¢ Red and yellow notification 
rates occur less than once per 
day 
â€¢ Device can monitor normal tissue while placed over a clear occlusive dressing with minimal 
impact on clinical alarm 
fatigue  
â€¢ Slightly higher notification rates 
than previous motion studies 
 Red Alarm Rate:   
â€¢ 0.44 red alarms / day  
â€¢ 1 red alarm every 2.28 days 
â€¢ 10 alarms in 548 hours  
 
Yellow-Only Alarm Rate:  
â€¢ 0.57 yellow alarms / day 
â€¢ 1 yellow alarm every 1.76 days  
â€¢ 13 alarms in 548 hours  
Optical Detection of 
Intravenous Infiltration:  A 
Pilot Study  
ivWatch Study ID:   
IVW400CS -09 
CCCHMC IRB ID : 2015- 0896 
Number of Subjects:  243 
Dates : August 2015 to July 
2016 1. Clinical trial in a childrenâ€™s hospital 
to demonstrate safety and efficacy in pediatric subjects.  
2. Time to detection â€“ estimate 
difference in time when infiltration is detected by clinician and ivWatch.  
3. Device sensitivity â€“ estimate 
ivWatch sensitivity at identifying infiltrations before the clinician.  
4. Notification Rate â€“ estimate of  the 
number of notifications per day without clinician -confirmed 
infiltrations.  â€¢ The device detected and 
alerted clinicians of infiltrations several hours before they are normally found by clinician assessment  
â€¢ The device performance did not depend on the age / size of the subject  Time to detection:  
â€¢ Median time difference: 15.2 hours  
â€¢ Range: 1.3 to 99.8 hours  
Sensitivity â€¢ 78.3% (18/23)  for Non -alarming 
group  
â€¢ 80.0% (12/15) for Alarming group  
Notification Rate â€¢ 0.28 red alarms / day  
â€¢ 0.27 yellow alarms / day 
 
 
  
IVW-CLR-CS27- 400 ivWatch SmartTouch Sensor:  
Device Validation  for Infiltrated Tissues  
 
CONFIDENTIAL  15 of 58 
Table 3. Clinical studies performed with SmartTouch sensor.  
Study  Purpose  Outcome  Key Performance Metrics  
Monitoring Infiltrated 
Tissues  
ivWatch Study ID:  IVW-CLR-
CS19- 400 
Chesapeake IRB ID:  00023277 
Number of Subjects:  64 
Number of Sites:  128 
Dates:  November  2018  
 1. Determine if infiltration signals 
measured with the SmartTouch 
sensor are equivalent to those measured with the Model 400 sensor.  
2. Contribute study data to a 
database of ivWatch signals of 
infiltrated tissue.  
3. Evaluate processing algorithms to 
optimize performance of the 
ivWatch infiltration detection 
algorithm.  
 â€¢ No statistical difference in the 
performance of the SmartTouch sensor versus the Model 400 fiber optic sensor, when accounting for catheter depth and distance using a linear regression model . 
â€¢ Catheter depth and distance were significantly different than IVW-CLR-CS06- 400, impacting 
sensitivity but not detection 
volume.  
 Red Alar m Sensitiv ity  
â€¢ 91.4% Sensitivity  
â€¢ Red Alarm in 117 out of 128 
cases  
Yellow Alarm Sensitivity  
â€¢ 93.0% Sensitivity  
â€¢ Yellow Alarm in 119 out of 128 cases  
Detected Volume (mean) â€¢ Red Alarm : 3.7mL 
â€¢ Yellow Alarm : 3.3mL  
Signal Variation of Normal 
Tissue   
ivWatch Study ID:  IVW-CLR-
CS20- 400CS  
Chesapeake IRB ID:  00023891 
Number of Subjects:  30 
Number of Sites:  30 
Dates:  December -January 
2018 1. Quantify the signal variation of 
normal tissue in a setting that 
approximates the hospital room 
environment. This includes 
calculating distribution metrics such 
as mean and standard deviation 
for the collected signals.  
2. Evaluate processing algorithms to 
optimize performance of the 
ivWatch device with SmartTouch 
sensor.  
3. Determine if non- infiltration red -
notification and yellow -notification 
rates are equivalent to those 
recorded with the Model 400  
sensor.  â€¢ The SmartTouch sensor has a 
similar false -notification 
performance to the Model 400 fiber optic sensor.  
â€¢ Both red and yellow estimated notification rates are within the 95% confidence intervals 
reported in â€œivWatch Model 
400: Device Validation for  Non-
Infiltrated Tissuesâ€.  Red Alarm Rate:   
â€¢ 0.312 red alarms / day 
â€¢ 95% confidence interval  0.133 to 
0.733 red alarms / day  
Yellow Alarm Rate:  
â€¢ 0.486 red alarms / day 
â€¢ 95% confidence interval: 0.176 to 
1.139 yellow alarms / day  
IVW-CLR-CS27- 400 ivWatch SmartTouch Sensor:  
Device Validation  for Infiltrated Tissues  
 
CONFIDENTIAL  16 of 58 
Device Verification for 
Infiltrated Tissues   
ivWatch Study ID:  IVW-CLR-
CS22- 400 
Chesapeake IRB ID:  00030567 
Number of Subjects:  128 
Number of Sites:  256 
Dates:  December  2018  
 1. Determine if infiltration  sensitivity 
measured with the SmartTouch 
sensor is equivalent to the Model 400 fiber optic sensor.  
2. Contribute study data to a 
database of ivWatch signals of 
infiltrated tissue.  
3. Evaluate processing algorithms to 
optimize performance of the 
ivWatch device w ith SmartTouch 
sensor.  Subject enrollment is complete . 
The data analysis is in progress . Analysis in progress  
Device Verification for Non -
Infiltrated Tissues  ivWatch Study ID:  IVW-CLR-
CS23- 400 
Chesapeake IRB ID:  00030569 
Number of Subjects:  30 
Number of Sites:  60 
Dates:  December 2018 â€“ 
January 2019  
 1. Quantify the non -infiltration red -
alarm and yellow -alarm rates for 
the SmartTouch sensor.  
2. Determine if non- infiltration red -
notification and yellow -notification 
rates of the SmartTouch sensor are equivalent to  the Model 400 fiber 
optic sensor.  
3. Evaluate signal processing 
algorithms to optimize performance 
of the ivWatch device with 
SmartTouch sensor.  
 Subject enrollment is complete . 
The data analysis is in progress.  Analysis in progress  
Device Verification for Non-
Infiltrated Tissues, Part II 
ivWatch Study ID: IVW -CLR-
CS26- 400 
Chesapeake IRB ID:  00032326 
Number of Subjects: 15  
Number of Sites: 30  
Dates: February â€“ March 2019 1. Quantify the non -infiltration red -
notification and yellow -notification 
rates for the SmartTouch sensor.  
2. Evaluate processing algorithms to 
optimize performance of the 
ivWatch device with the 
SmartTouch sensor.  
3. Determine if non- infiltration red -
notification and yellow -notification 
rates are equivalent to those 
recorded with the Model 400 
sensor . Enrollment is open, 11/15 
accepted case studies complete to date .  Analysis in progress  
IVW-CLR-CS27- 400 ivWatch SmartTouch Sensor:  
Device Validation  for Infiltrated Tissues  
 
CONFIDENTIAL  17 of 58 
The Effect of PIV Depth and 
Site 
ivWatch Study ID: IVW -CLR-
CS25- 400 
Chesapeake IRB ID : 00032269 
Number of Subjects:  64 
Number of Sites:  128 
Dates: March 2019  1. Determine whether the catheter 
depth has a significant effect on 
the measured infiltration signal.  
2. Determine whether the catheter site has a significant effect on the measured infiltration signal.  
3. Contribute study data to a database of ivWatch signals of  
infiltrated tissue.  
4. Evaluate processing algorithms to optimize performance of future 
ivWatch devices.  Subject enrollment is finished for 
this study. The data analysis is in progress.  Analysis in progress  
IVW-CLR-CS27- 400 ivWatch SmartTouch Sensor:  
Device Validation  for Infiltrated Tissues  
 
CONFIDENTIAL  18 of 58 
Study Goals and Objectives  
The goal of this study is to validate the performance of the ivWatch SmartTouch sensor for 
detecting the early stages of an IV infiltration, as collected from healthy adult volunteers. The Model 400 Fiber Optic sensor is used for performance comparison. The study objectives include:  
Primary Objective : Demonstrate a statistically signi ficant improvement for detecting early stage 
infiltrations in comparison to hourly observation by a perfect clinician.  
Secondary Objectives : 
1. Demonstrate statistical equivalence in infiltration detection volume of the SmartTouch and Fiber Optic sensors.  
2. Dem onstrate statistical equivalence in infiltration sensitivity of the SmartTouch and Fiber 
Optic sensors.  
Study Design 
Approximately 115 subjects may be enrolled in the study with the goal of achieving 98 accepted 
case studies . The study coordinator will attempt to enroll at least 20 subjects (20%) with dark skin 
pigmentation and at least 20 subjects (20%) who are classified as obese by their body mass index 
(BMI) , but these are not required enrollment criteria as skin pigmentation and BMI have proven to 
be insignificant variables in previous ivWatch studies . The intent is to include subjects with different 
skin pigmentations and body types such that the study represents the intended population of the device. The duration of each study depends on the random ly selected infiltration rates. A study 
may take up to 2 hours to complete. This corresponds to the subjects receiving the 5mL/hr 
infiltration rate.  
Medical professionals  will be used for the health screening of the subject and placement of the 
catheters.  If the research subject is deemed acceptable for the study, various metrics of each 
subject will be measured, as summarized in Figure 4. These measur ements include the weight, 
height, blood pressure, forearm circumference, skin tone (light, medium, or dark), and skin 
classification. The skin classification is performed by using the subject pigmentation worksheet to determine the subjectâ€™s Fitzpatrick s kin type. The subjectâ€™s body mass index is calculated from the 
weight and height measurements and is used as a measure of the subjectâ€™s body type (underweight, normal, overweight, obese). These metrics are recorded for post -study analysis to 
identify corre lations between the measured signal and anatomical/physiological characteristics 
of the research subjects.  
IVW-CLR-CS27- 400 ivWatch SmartTouch Sensor:  
Device Validation  for Infiltrated Tissues  
 
CONFIDENTIAL  19 of 58 
 
Figure 4. Pre-study measurements performed on each subject.  
After completing the informed consent and health history forms, the subject is taken to the test 
room, which is designed to approximate an infusion center . The room also includes two IV pumps 
and two ivWatch patient monitors per subject . The study configur ations have been randomized 
and are included in  Table 4.  
During the study, each subject will receive two subcutaneous injections of isotonic saline solution. These injections will be randomly selected from the four possible locations shown in Figure 5. These 
four locations represent the most common injection sites for PIV therapy. The subcutaneous injections closely approximate the conditions of a PIV infiltration without exposing the research subject to additional risks and discomforts associated with puncturing a vein (e.g. ecchymosis, 
hematoma, phlebitis, thrombosis, embolism). The subcutaneous injections will be performed using the same equipment as a PIV procedure.   
 
Figure 5. The four possible anatomical sites monitored during this study.  
  

IVW-CLR-CS27- 400 ivWatch SmartTouch Sensor:  
Device Validation  for Infiltrated Tissues  
 
CONFIDENTIAL  20 of 58 
Table 4. The study configuration.  
CRF Site Rate  Fiber Optic 
Side SmartTouch 
Side   CRF Site Rate  Fiber Optic 
Side SmartTouch 
Side 
1 Forearm  50 Left Right    50 Forearm  25 Left Right  
2 Hand  5 Right  Left   51 Hand  25 Right  Left 
3 Forearm  5 Left Right    52 Hand  50 Left Right  
4 Forearm  100 Left Right    53 Hand  75 Right  Left 
5 Hand  75 Left Right    54 Forearm  125 Left Right  
6 Forearm  150 Left Right    55 Hand  100 Left Right  
7 Hand  125 Left Right    56 Forearm  75 Left Right  
8 Hand  150 Right  Left   57 Hand  75 Left Right  
9 Hand  100 Right  Left   58 Hand  5 Right  Left 
10 Forearm  100 Right  Left   59 Forearm  150 Left Right  
11 Hand  50 Right  Left   60 Forearm  25 Right  Left 
12 Forearm  150 Right  Left   61 Forearm  75 Right  Left 
13 Forearm  50 Right  Left   62 Hand  150 Right  Left 
14 Hand  100 Left Right    63 Hand  75 Right  Left 
15 Hand  100 Right  Left   64 Forearm  100 Left Right  
16 Hand  5 Left Right    65 Hand  100 Right  Left 
17 Forearm  5 Right  Left   66 Hand  125 Left Right  
18 Forearm  100 Left Right    67 Hand  25 Left Right  
19 Hand  5 Right  Left   68 Forearm  25 Left Right  
20 Forearm  5 Left Right    69 Forearm  5 Left Right  
21 Forearm  125 Right  Left   70 Forearm  100 Right  Left 
22 Hand  50 Left Right    71 Forearm  50 Left Right  
23 Forearm  50 Left Right    72 Hand  50 Right  Left 
24 Hand  150 Left Right    73 Hand  100 Left Right  
25 Hand  125 Right  Left   74 Forearm  75 Left Right  
26 Forearm  125 Left Right    75 Forearm  50 Right  Left 
27 Forearm  75 Right  Left   76 Hand  50 Left Right  
28 Forearm  150 Left Right    77 Forearm  150 Right  Left 
29 Hand  125 Left Right    78 Forearm  50 Left Right  
30 Forearm  25 Right  Left   79 Hand  150 Left Right  
31 Hand  75 Right  Left   80 Forearm  150 Left Right  
32 Hand  25 Left Right    81 Forearm  125 Right  Left 
33 Forearm  25 Left Right    82 Hand  75 Left Right  
34 Forearm  125 Right  Left   83 Hand  5 Left Right  
35 Hand  50 Right  Left   84 Forearm  5 Right  Left 
36 Hand  5 Left Right    85 Hand  25 Right  Left 
37 Hand  125 Right  Left   86 Hand  5 Right  Left 
38 Forearm  5 Right  Left   87 Hand  50 Right  Left 
39 Forearm  50 Right  Left   88 Hand  125 Right  Left 
40 Hand  150 Right  Left   89 Hand  150 Right  Left 
41 Forearm  100 Right  Left   90 Hand  25 Left Right  
42 Forearm  150 Right  Left   91 Forearm  75 Right  Left 
43 Hand  25 Right  Left   92 Forearm  125 Left Right  
44 Forearm  25 Right  Left   93 Forearm  100 Left Right  
45 Forearm  75 Left Right    94 Hand  125 Left Right  
46 Hand  25 Left Right    95 Forearm  5 Left Right  
47 Hand  75 Left Right    96 Hand  100 Right  Left 
48 Hand  150 Left Right    97 Forearm  125 Right  Left 
49 Forearm  75 Right  Left   98 Forearm  25 Right  Left 
 
IVW-CLR-CS27- 400 ivWatch SmartTouch Sensor:  
Device Validation  for Infiltrated Tissues  
 
CONFIDENTIAL  21 of 58 
All subcutaneous injections in this research protocol are infiltrated between 5mL/hr and 150mL/hr, 
as listed in  Table 4. Each injection is limited to a total of 10 mL of saline solution to minimize subject 
discomfort. This 10mL volume limit corresponds to a 2 hour infiltration at the 5 mL/hr IV pump rate 
and a 4 minute infiltration at the 150mL/hr IV pump rate.  
The nurse will examine each site before placing the IV catheters. Photographs of the illumination 
by a NIR vein viewer will be captured as a record o f the subjectâ€™s vascular structure at the site. 
The nurse will place the IV catheters at approximately the same anatomical location on each arm. The catheter depth will be monitored and recorded using the SonoSite S -Series ultrasound 
imaging system, shown in Figure 6. The nurse places the catheter immediately adjacent to a vein 
typically used for IV therapy. Placing the catheter tip close to the vein wall ensures the saline diffuses similar to a real -world infiltration.  
 
Figure 6. The Sonosite S -Series commercial ultrasound imaging system.  
After placement of the catheter, each subject will receive the SmartTouch sensor on one side and 
the Model 400 fiber optic sensor on the other side according to the random study configuration. 
The sensor is placed next to the injection site. An example of the ivWatch SmartTouch sensor is 
shown in Figure 7. The nurse will dress the site using standard hospital procedures and occlusive 
dressings. Photographs will be captured to record the position of the sensor with respect to the catheter. The sensor cable will be taped to the IV tubing and rout ed to the IV pole. The IV tubing 
/ ivWatch sensor cable bundle will be secured to the subject using medical tape following standard hospital procedures.  

IVW-CLR-CS27- 400 ivWatch SmartTouch Sensor:  
Device Validation  for Infiltrated Tissues  
 
CONFIDENTIAL  22 of 58 
 
Figure 7. Example of the ivWatch SmartTouch sensor  
 
The sensor is connected to the IPM . A rendering of the patient monitor is included in Figure 8. The  
rendering identifies the user interface elements on the front face of the IPM. The IPM is attached 
to the IV pole. The IPM records data during the study and is attached to the IV pole.  
Once the ivWatch sensors have been placed on the subject, data acquisition will be started on 
the two ivWatch patient monitors. This represents t ime zero (t = 0) in the study. Study staff will record 
the timing of study events (starting and stopping IPMs, starting and stopping pumps) using a digital 
wall clock.  The pumps will be turned on after 5 minutes of monitoring. The IV pumps will stop after 
10mL of isotonic saline solution has been injected into the tissue. Once the pumps have been 
stopped for both sites, the IPMs will collect data for an additional 5 minutes.  
Once the data acquisition is complete, the research assistant  captures photographs of the two 
sites to record the visual appearance of the region. The ivWatch components are removed from 
the sites. An ultrasound technician will then capture ultrasound images of the sites to record 
structure of the infiltrated tissue under the sensor and measure catheter depth . The IVâ€™s are then 
removed from the research subject. A final photograph is captured of the bare sites. The photographs are intended to record the skin integrity, such as whether the research subject had an allergic reaction to any m aterials or if the skin was damaged when removing adhesive- backed 
sensors.  
ivWatch, LLC believes this study design provides the signal characteristics that are representative of those expected in a clinical setting. This data will enable the researchers to  understand 
differences, if any, between the optical signal characteristics of infiltrated tissue data collected with the SmartTouch sensor versus the Model 400 sensor.  

IVW-CLR-CS27- 400 ivWatch SmartTouch Sensor:  
Device Validation  for Infiltrated Tissues  
 
CONFIDENTIAL  23 of 58 
 
Figure 8. The ivWatch Patient Monitor with extension module and user interface elements.  
Methodology  
Subject Recruitment 
Previous  research participants of ivWatch clinical studies will be recruited to participate in the 
study. Advertisements are not needed to obtain the number of accepted case studies. The study 
will be limited to healthy adult volunteers (18 years or older). During  the initial recruitment,  
interested participants will be provided an overview of the study and an initial pre- screen will be 
completed. If eligibility is unclear during the pre-screening process, the registered nurse can 
consult the chief nursing officer or  investigator to determine eligibility. The pre -screening form is 

IVW-CLR-CS27- 400 ivWatch SmartTouch Sensor:  
Device Validation  for Infiltrated Tissues  
 
CONFIDENTIAL  24 of 58 
included on page 42. If the participant is interested in the study, 18 years or older, and deemed 
an acce ptable research subject, a time and date for the study will be scheduled with the subject. 
The formal consent and screening process will be performed on the day of the study, as described 
in the following section.  
Preliminary Information and Consent 
The pr e-study procedure is listed in detail on p age 46. Once arriving at the study site, the subject 
fills out a sign -in sheet indicating their name and the time of their arrival. The subject is then taken 
to a private screening room. A research assistant will w elcome the subject and provide the 
informed consent document. The research assistant  will discuss the main points of the study  and 
the subjectâ€™s rights, as described in the consent form.  
If the subject understand s and signs the consent form, the subject wi ll be asked to fill out a  
participant health history form. The purpose of the health history form is to prevent potentially sick 
or unhealthy subjects from participating in the trial.  Each subject must complete the health and 
consent forms before participating in the study.  As part of the health history form, the nurse  will 
measure the body  temperature of the subject with the goal of preventing sick individuals from 
participating in th e study.  
The nurse  reviews the subjectâ€™s health report form to determine if the subject qualifies for the study. 
A list of exclusion criteria is included in Table 5. Any additional concerns or questions will be 
directed to the on -staff chief nursing officer and/or medical doctor. They  may use their  
professional judgment to exclude a subject for reasons not included in this list of exclusion criteria.  
Table 5. List of study exclusion criteria . 
1 Abnormal bleeding / hemophilia  
2 Absence of sensation in arms  
3 Anemia  
4 Cardiopulmonary disorders  
5 Clotting disorders  
6 Currently pregnant  
7 Dehydration  
8 Dizziness or fainting  
9 Hepatitis  
10 HIV / Aids  
11 Immune Deficiency Disorders  
12 Lymphedema  
13 Major surgery or scar tissue which would complicate PIV access  
14 Radiation / chemotherapy  within last year  
15 Received IV therapy in last 14 days  
16 Seizures  
17 Stroke  
18 Sick or had infection in past 14 days  
19 High Temperature (>99.6Â°F)  
20 Blood thinning medication (e.g. aspirin regimen, Coumadin, warfarin)  
21 Tattoos covering more than half of back of hand or inner forearm  
 
IVW-CLR-CS27- 400 ivWatch SmartTouch Sensor:  
Device Validation  for Infiltrated Tissues  
 
CONFIDENTIAL  25 of 58 
If the subject completes the informed consent document  and the health history report form  is 
approved , then the first three sections of the case report form should be  completed, which 
includes general study information, inclusion criteria, and subject information . An example of the 
case report  form is included in the Case Report Form section of this research protocol.  
Several metrics of the subjectâ€™s body are measured as a record of the body type and physiology. 
These metrics include body weight, height, blood pressure, and circumference of the forearm. 
The body metrics are recorded in Section 4 of the case report form.  The research assistant  will also 
work with the subject to complete a subject pigmentation worksheet. The  results of this worksheet 
are recorded in Section 5 of the case report fo rm. 
The selected study configuration information  (Table 5) is recorded in Section 6 of the case report 
form and the serial numbers of the ivWatch patient monitors , extension module,  sensor cables, 
and receptacle  are recorded in Section 7 of the case report  form.  
Data Collection 
The data collection checklist is included on page  47. The data collection consists of three 
processes: (1) subject preparation, (2) data collection, and (3) study completion.  
Subject Preparation  
Once the preliminary information is collected, the subject will be taken to the test area. The nurse and ultrasound tech will perform hand hygiene and put on latex -free medical -grade gloves. Each 
subject has two injection sites. The sites are prepared using the same procedure, except one site 
will use the SmartTouch  sensor and one site will use the fiber optic sensor . The nurse and research 
assistant  will examine the potential sites. A photograph of the VeinViewer illumination will be 
captured as a record o f the vascular structure at the site. A second photograph will be captured 
of the bare site where the injection will occur. This photograph will be compared to a post -study 
photograph to see if there is any skin irritation associated with the ivWatch senso r. The filenames 
of these photographs are recorded in Section 7 of the case report form.  
Using protocols based on hospital procedures, the nurse cleans the site with a CHG swabstick for 30 seconds and allows to air dry for 30 seconds. The nurse inserts the  catheter next to a vein that 
would typically be used for a PIV therapy. Once the insertion is complete, a shallow high -resolution  
ultrasound image of the catheter and surrounding tissue is captured. The image should show as much of the catheter length as possible, while also including the catheter tip. The depth of the catheter tip relative to the skin surface is measured and the corresponding image is saved. The ultrasound image File ID and the measured depth are recorded in the case report form.  
The nurs e places the ivWatch sensor  within 5 mm  of the approximate location of the catheter tip. 
After sensor and occlusive dressing placement, the sensor cable and IV tubing are secured to the subjectâ€™s arm using medical tape.  
Once complete, the research assistan t will capture a photograph of the dressed site. This 
photograph can be used to measure the separation between the catheter tip and the ivWatch sensor in a post study analysis. The nurse will measure the circumference of each site. The photograph file ID a nd circumference are recorded in the case report form.  
IVW-CLR-CS27- 400 ivWatch SmartTouch Sensor:  
Device Validation  for Infiltrated Tissues  
 
CONFIDENTIAL  26 of 58 
Data Collection 
After both sites have been set up, the nurse will start the data acquisition  on the ivWatch patient 
monitors (t=0). A digital clock is used to record the ivWatch acquisition and infiltr ation start times. 
The acquisition start times are recorded in the case report form. The IPMs collect data for 5 minutes.  
After the normal acquisition period is complete, the IV pumps are started at their specified rate 
(either 5, 25, 50, 75, 100, 125, or 150 mL/hr). The pumps will stop automatically after a total of 10mL of isotonic saline is pumped into the subcutaneous tis sue. The stop times will be recorded in the 
case report form. The data acquisition will be stopped on the two IPMs five minutes after the slower of the two infiltrations is complete. The research assistant  will record the times of these actions in 
Section 8 of the case report form.  
 
End of Study  
Once the ivWatch data acquisition is complete, additional data is recorded from both sites. First, a post study circumference measurement of the site is performed by the nurse and recorded in the case report form. Then, a photograph is captured of the injection site as a record of the visual swelling. The file identification information of this photogra ph is recorded in the case report form.  
The occlusive dressing and ivWatch sensor are carefully removed from the injection site without pulling out the catheter. The research assistant  captures a photograph of the VeinViewer 
illumination and records the photo ID in the case report form. A series of ultrasound images are captured to record the state of the tissue under the sensor. The file identification information for the ultrasound image is recorded in the case report form. Once the ultrasound imaging is  
complete, the catheter is removed. Light pressure is applied if there is any bleeding (usually there is no bleeding since this is a subcutaneous injection). A final photograph is captured of the site as a record of skin integrity and whether the ivWatch sensor caused any irritation to the skin. An adhesive bandage is applied to the site.  
Once this procedure has been completed for both sites, the research assistant  completes the 
remaining sections of the case report form, which include areas for adding misc ellaneous notes, 
a description of any device deficiencies/malfunctions  that occurred , a description of any adverse 
events  that occurred , and an area for an investigator  to authorize the case report form.  Once the 
case report form is complete, the subject i s taken to the front reception desk and given the 
participation payment. The subject is asked to sign and date a check- out sheet to verify receipt 
of payment. A copy of their informed consent form with c ontact information will be given to the 
subject should they have any questions or concerns after departing ivWatch.  
The research assistant  is responsible for cleaning and re- organizing the test area after the subject 
has departed. This includes removing tape connecting the IV tubing to the ivWatch sensor, disposing the used IV tubing, and cleaning the ivWatch sensor and monitor with hospital -grade 
disinfectant wipes. Data saved during the study will be removed from the corresponding machines and saved to a secure network server. The data includes IPM data (tr ansferred via USB 
drive), ultrasound images (transferred via USB drive), and camera images.  
IVW-CLR-CS27- 400 ivWatch SmartTouch Sensor:  
Device Validation  for Infiltrated Tissues  
 
CONFIDENTIAL  27 of 58 
The research assistant  will store all paperwork from the study (case report forms, subject 
pigmentation forms) in a manila folder in a secure location. All paperwor k containing private 
health information is given to the HIPAA officer  or designee  for separate and secure storage.  
Data Analysis 
After the study is complete, a series of analyses will be performed on the collected ivWatch data. 
Specific statistical tests and rationale are included in the Statistical Considerations section of this protocol (page 31).  
Possible reasons a study may be rejected include, but are not limited to:  
1. Equipment (infusion pump, catheter, patient monitor) not operating properly. 
2. Leaking catheter or IV site.  
3. Early termination by research subject.  
4. Sensor placement more than 2 cm from the catheter tip.  
5. Significant deviations from research protocol.  
All data analyses will be independently reviewed and verified by a second researcher.  
Risk Ben efit Analysis  
Injection of Isotonic Saline 
The study design is considered to have minimal risk to the healthy adult volunteers participating in this study. Previous studies have generated infiltrations by intentionally pushing the needle through the vein w all into the surrounding subcutaneous tissue. The placement of the needle into the vein 
introduces additional risks such as ecchymosis, hematoma, phlebitis, thrombosis, and embolism. This study generates an infiltration by performing subcutaneous injections of isotonic saline solution. This method of generating infiltrations is believed to be much safer for the research subject, including being less painful than puncturing a vein wall.  
The most likely complication associated with subcutaneous injections wou ld be an infection. The 
risk of an infection is reduced by (1) only enrolling healthy adult volunteers (that is, subjects are not immunocompromised) and (2) using safe procedures based on standard hospital practices (PIV therapy) and medical -grade sterile materials (e.g. ultrasound gel, occlusive dressing). 
Another complication could include hitting a nerve causing significant pain for the subject. This risk is minimized by using an experienced nurse to perform the injections at common sites for PIV therapy . 
A registered nurse or physician  with significant PIV therapy experience will perform all of the 
injections and will be onsite throughout the study. ivWatch, LLC has two medical doctors available 
by phone  should any medical related questions arise during a study. 
Infusion of saline solution into the subcutaneous tissue does not pose a significant risk to the study subjects. Hypodermoclysis is a common medical practice of injecting saline into subcutaneous tissues for treatment or prevention of dehydration. This is typically used for elderly patients. Hypodermoclysis is performed on a variety of sites including back, abdomen, and upper regions 
IVW-CLR-CS27- 400 ivWatch SmartTouch Sensor:  
Device Validation  for Infiltrated Tissues  
 
CONFIDENTIAL  28 of 58 
of the arms and legs. Pump rates range from 20 to 125mL/hr with a total delivered volume less 
than 1500mL in a 24 hour period  [10]. In comparison to the hypodermoclysis procedure, the studyâ€™s 
10mL maximum volume and 5 to 150 mL /hr flow rates of 0.9% saline do not pose a significant 
health risk to the study subjects.  
The ivWatch Technology 
The ivWatch technology is a non- signifi cant risk device as determined by the FDA. In a face -to-
face meeting with the FDA on March 28, 2014, the FDA classified the ivWatch Model 400 as a Class II, NSR device. The ivWatch Model 400 has received marketing clearance from the FDA for adults and pediatrics . Earl y prototypes  of the Model 400  were evaluated in previous clinical studies with 
IRB approval. A list of these studies is included in  Table 6. 
The electronic  sensor is designed to perform identically to the Model 400 fiber optic sensor.  The 
materials used for the electronic sensor are common medical grade materials and are generally 
regarded as safe. The amount of LED light emitted by the sensor into the patientâ€™s skin is significantly less than the maximum permissible ocular and skin exposures published in the ANSI Z136.1 Laser safety standard. To our knowledge, there is no standard regulating the safety of LED emitting products, so the laser safety standard h as been used to demonstrate the safety of the 
emitted optical powers.  The amount of heat generated by the LEDs in the sensor head is much 
lower than conventional pulse oximeters, due to a low duty cycle and optical power, as well as an optimized photodiode  amplification circuit.  
 
IVW-CLR-CS27- 400 ivWatch SmartTouch Sensor:  
Device Validation  for Infiltrated Tissues  
 
CONFIDENTIAL  29 of 58 
Table 6. Clinical trials involving the ivWatch technology.  
STUDY  SPONSOR  INVESTIGATOR  IRB NO.  
Healthy adult volunteer study & 
nurse focus group  CW Optics  University of Virginia 
Medical Center  HIC11383 
Adult patient study  CW Optics  Virginia Commonwealth 
University Medical Center  HM12146 
Pediatric Study  ivWatch, LLC  Cincinnati Childrenâ€™s 
Hospital Medical Center  2009- 2550  
NIR Detection of PIV Infiltration  ivWatch, LLC  ivWatch, LLC  Chesapeake IRB 
ID: 00008513  
The Signal Variation of Normal 
Tissue  ivWatch, LLC  ivWatch, LLC  Chesapeake IRB 
ID: 00008218  
The Effect of Catheter Depth  ivWatch, LLC  ivWatch, LLC  Chesapeake IRB 
ID: 00008254  
The Effect of Infiltration Rate ivWatch, LLC  ivWatch, LLC  Chesapeake IRB 
ID: 00008941  
Long Term Adhesion of the 
ivWatch Receptacle  ivWatch, LLC  ivWatch, LLC  Chesapeake IRB 
ID: 00008891  
Device Validation for Non -
Infiltrated Tissues  ivWatch, LLC  ivWatch, LLC  Chesapeake IRB 
ID: 00009175  
Device Validation for Infiltrated 
Tissues  ivWatch, LLC  ivWatch, LLC  Chesapeake IRB 
ID: 00009285  
The Effect of Sensor -to-Catheter 
Distance  ivWatch, LLC  ivWatch, LLC  Chesapeake IRB 
ID: 
00010217  
Infiltration Detection when 
Placing Over the Dressing  ivWatch, LLC  ivWatch, LLC  Chesapeake IRB 
ID: 00013715  
Performance for Non -Infiltrated 
Tissues when Placing Over 
Transparent Occlusive Dressing  ivWatch, LLC  ivWatch, LLC  Chesapeake IRB 
ID: 00015068  
Optical Detection of Intravenous 
Infiltration: A Pilot Study  ivWatch, LLC  Cincinnati Childrenâ€™s 
Hospital Medical Center  2015 -0896  
 
ivWatch SmartTouch Sensor: 
Monitoring Infiltrated Tissues  ivWatch, LLC  ivWatch, LLC  Chesapeake IRB 
ID: 00023891  
ivWatch SmartTouch Sensor: 
Signal Variation of Normal Tissue  ivWatch, LLC  ivWatch, LLC  Chesapeake IRB 
ID: 00023277  
ivWatch SmartTouch Sensor: 
Device Verification for Infiltrated 
Tissues  ivWatch, LLC  ivWatch, LLC  Chesapeake IRB 
ID: 00030567  
ivWatch SmartTouch Sensor: 
Device Verification for Non -
Infiltrated Tissues  ivWatch, LLC  ivWatch, LLC  Chesapeake IRB 
ID: 00030569  
IVW-CLR-CS27- 400 ivWatch SmartTouch Sensor:  
Device Validation  for Infiltrated Tissues  
 
CONFIDENTIAL  30 of 58 
ivWatch SmartTouch Sensor: 
Device Verification for Non -
Infiltrated Tissues, Part II  ivWatch, LLC  ivWatch, LLC  Chesapeake IRB 
ID: 00032326  
ivWatch SmartTouch Sensor: The 
Effect of PIV Depth and Site  ivWatch, LLC  ivWatch, LLC  Chesapeake IRB 
ID: 00032269  
 
 
Follow -Up 
There is no anticipated need for a follow -up protocol after this study. Prior to departure, the 
research personnel will provide the subject  with contact information should they have any 
questions or concerns after leaving the study.  
Data Management and Statistical Considerations  
Data Management 
The data management process includes recording data during the study, transferring data to a 
secure electronic database, and data validation. 
Five forms of data are recorded during each study: 
1. Information on the health of the study subject is recorded in the health history form. This form is provided in the Participant Health History Form section of thi s document. This form 
is completed by the subject prior to the study. The form requests only information relevant to the study. The health history form is stored in a locked filing cabinet at the ivWatch facility.  
2. Study -related information is recorded usin g the studyâ€™s case report form ( including the 
subject activity log ). The case report form includes study information (gender , age, body 
measurements, skin classification, product serial numbers, times, and filenames).  
This form is completed by the researc h assistant  during the study. The case report form 
does not include any personal identifiers. The original forms are stored at the ivWatch facility.  
3. The ivWatch data is recorded using the investigational device that store the data 
internally. The filename does not contain any personal identifiers.  
4. The ultrasound images are saved to the ultrasound machine during the study. The filename does not contain any personal identifiers.  
5. Digital photographs and video images are recorded throughout the study . The filenames 
do not contain personal identifiers although the subjects may be identifiable in the images. The informed consent form discloses the collection of photographic images and 
video recordings . 
Once a study is complete, the case report form data, the ivWatch data, ultrasound images, and 
camera images are transferred to an electronic database. The ultrasound and photographic images are deleted from the ultrasound machine and digital camera, respectively. The database 
IVW-CLR-CS27- 400 ivWatch SmartTouch Sensor:  
Device Validation  for Infiltrated Tissues  
 
CONFIDENTIAL  31 of 58 
has been designed such that no perso nal identifiers are available to match a study dataset with 
a particular subject. To protect the confidentiality and integrity of the data, the password -
protected database can only be accessed by authorized users. The privileges of each authorized 
user are  set by the database administrator. All changes made to the database are recorded in 
an audit log. The log includes (but is not limited to) which fields were changed and which user made the changes. This audit trail is necessary for data integrity as well as meeting regulatory guidelines. Double data entry by two people is used to verify that data is correctly entered into the database. After validation is complete, the database will be available to the authorized users.  
Statistical Considerations 
The goal of this study is to validate the performance of the ivWatch SmartTouch sensor for detecting the early stages of an IV infiltration, as collected from healthy adult volunteers. The Model 400 Fiber Optic sensor is used for performance comparison. The study o bjectives include:  
Primary Objective : Demonstrate a statistically significant improvement for detecting early stage 
infiltrations in comparison to hourly observation by a perfect clinician.  
Secondary Objectives : 
1. Demonstrate statistical equivalence in infiltration detection volume of the SmartTouch and Fiber Optic sensors.  
2. Demonstrate statistical equivalence in infiltration sensitivity of the SmartTouch and Fiber Optic sensors.  
Primary Objective  
The primary objective is to demonstrate a statistically significant improvement in the sensitivity for early stage infiltrations compared to the current nursing standard of care, where the performance of the current nursing standard is estimated using the concept of a perfect clinician. The perfect clinician assesses the IV site hourly and perfectly classifies the tissue as normal or infiltrated 
regardless of the volume of fluid that has been infiltrated.  The performance of the perfect clinician can be theoretically calculated. For the study configuration listed in Ta ble 7, the perfect clinician 
would capture 28.2% of the infiltrations prior to an infiltrated volume of 10mL.  
Table 7. The study configuration for the infiltration study  
Rate 
(mL/hr)  Number of 
Subjects  Perfect 
Clinician 
Sensitivity (%) Number of Early Infiltrations 
Detected by Perfect 
Clinician  
5 14 100.0  14.0 
25 14 40.0 5.6 
50 14 20.0 2.8 
75 14 13.3 1.9 
100 14 10.0 1.4 
125 14 8.0 1.1 
150 14 6.7 0.9 
 
IVW-CLR-CS27- 400 ivWatch SmartTouch Sensor:  
Device Validation  for Infiltrated Tissues  
 
CONFIDENTIAL  32 of 58 
A Monte Carlo simulation was performed to evaluate the hypothesis test comparing the perfect 
clinician (H 0) and a device with a sensitivity of 90% (H 1). The 90% sensitivity is a conservative 
assumption based on sensi tivities measured in previous ivWatch studies . A total of one million trials 
were simulated using the study con figuration shown in Table 7.  The infiltration detection times for 
the perfect clinician were uniformly distributed between 0 and 60 minutes. The perfect clinician provided early detection of an infiltration if the detection time was less than the time req uired to 
infiltrate 10mL at the given rate. The simulation code is included in the Statistical Monte Carlo 
Analysis Appendix (page 56) . Figure 9 shows the results of the Monte Carlo analysis. A threshold of 
35% corresponded to an alpha of 0.04 1 (0.05 was not possible due to the discrete nature of the 
sampled sensitivities), that is, 95. 9% of the null hypothesis trials (perfect clinician) had sensitivitie s 
less than 35%.  
 
Figure 9. The Monte Carlo simulation of a device operating with an infiltration sensitivity 
equivalent to the perfect clinician (null hypothesis) and a device operating at a 90% sensitivity 
(alternative hypothesis). The red line shows the location of Î±=0.04 1 thresh old (one -sided).  
Figure 10 shows the statistical power analysis for this Monte Carlo simulation. A statistical power 
exceeding 90% was calculated for ivWatch device sensitivities greater than 4 2%. For the specific 
alternative hypothesis of 90% sensitivity, the statistical power was estimated to be essentially 100%. A sample size of 98 is assumed in this simulation, which is based on the detection volume  
comparison objective. In addition to the large statistical power, a sample size of 98 also provides 
a reasonable confidence interval on our estimated sensitivity. For a sensitivity of 9 1% (89/98) , the 
95% confidence interval would be 0.83 to 0.96 .  

IVW-CLR-CS27- 400 ivWatch SmartTouch Sensor:  
Device Validation  for Infiltrated Tissues  
 
CONFIDENTIAL  33 of 58 
  
Figure 10. The statistical power for a 98 PIV site study as a function of the device sensitivity 
(specific alternative hypothesis). 
The hypothesis test for a binomial distribution will be performed following the study to ensure the 
measured sensitivities of both sensors are significantly greater (alpha = 0.05) than the perfect 
clinician.  
Secondary Objectives  
Detection Volume Comparison  
The first secondary objective is to demonstrate equivalent detection volume between the SmartTouch (ST) and Fiber Optic (FO) sensor. In the clinical study ivWatch Model 400: Validation 
for Infiltrated Tissues  (FO sensor), where the same infusion rate confi guration from Table 7 was 
implemented, the mean and standard deviation detection volume was found to be in 3.75 mL Â±2.13 mL. In order to test if the mean detection volume for the ST sensor ( Î¼
ST) is less than or equal 
to  the mean detection volume of the FO  sensor ( Î¼FO) with a margin of error ( Î”0), the following 
single -sided hypothesis test configuration is used:  
Null Hypothesis ( H0): Î¼FO- Î¼ST = Î” 0 
Alternative Hypothesis (H 1): Î¼FO- Î¼ST > Î”0 
The sample size (n) needed to show equivalence is defined by the fol lowing equation:  
ð‘›ð‘›=(ð‘§ð‘§ð›¼ð›¼+ð‘§ð‘§ð›½ð›½)2(ðœŽðœŽð¹ð¹ð¹ð¹2+ðœŽðœŽð‘†ð‘†ð‘†ð‘†2)
(âˆ†âˆ’âˆ†0)2 
where Î” is the difference in means (Î¼ FO - Î¼ST), and Ïƒ the standard deviation of each sensor. The 
ÏƒST is estimated to be equal to Ïƒ FO. The margin of error (Î” 0) is assumed to be 1.0 mL, which is less 
than half of the standard deviation. An analysis of statistical power versus sample size is shown in Figure 11, (alpha = 0.05). A sample size of 98 subjects will provide a statistical power of 95%. Sample 

IVW-CLR-CS27- 400 ivWatch SmartTouch Sensor:  
Device Validation  for Infiltrated Tissues  
 
CONFIDENTIAL  34 of 58 
size for t his clinical study is based on this objective. Following the study a single -sided studentâ€™s t -
test will be used to compare the sensor detection volumes.  
 
Figure 11. Statistical power vs sample size for detection volume comparison  
Sensitivity Comparison  
Approximate confidence intervals for the difference in sensor sensitivities (p FO â€“ p ST) will be found 
using the following equation:  
ð‘ð‘ð¹ð¹ð¹ð¹âˆ’ð‘ð‘ð‘†ð‘†ð‘†ð‘†âˆ’ð‘§ð‘§ð›¼ð›¼ï¿½ð‘ð‘ð¹ð¹ð¹ð¹(1âˆ’ð‘ð‘ð¹ð¹ð¹ð¹)
ð‘›ð‘›ð¹ð¹ð¹ð¹+ ð‘ð‘ð‘†ð‘†ð‘†ð‘†(1âˆ’ð‘ð‘ð‘†ð‘†ð‘†ð‘†)
ð‘›ð‘›ð‘†ð‘†ð‘†ð‘† â‰¤ ð‘ð‘ð¹ð¹ð¹ð¹âˆ’ð‘ð‘ð‘†ð‘†ð‘†ð‘†â‰¤ ð‘ð‘ð¹ð¹ð¹ð¹âˆ’ð‘ð‘ð‘†ð‘†ð‘†ð‘†+ð‘§ð‘§ð›¼ð›¼ï¿½ð‘ð‘ð¹ð¹ð¹ð¹(1âˆ’ð‘ð‘ð¹ð¹ð¹ð¹)
ð‘›ð‘›ð¹ð¹ð¹ð¹+ ð‘ð‘ð‘†ð‘†ð‘†ð‘†(1âˆ’ð‘ð‘ð‘†ð‘†ð‘†ð‘†)
ð‘›ð‘›ð‘†ð‘†ð‘†ð‘† 
In order for the ST sensor to be equivalent (â‰¥) the FO sensor, the lower bound of the confidence 
interval should be < 0. Figure 12 illustrates a range of possible confidence intervals in a study with 
nFO = n ST = 98, an d a p FO = 96%. In this case, if the ST sensitivity (p ST) is 89% or lower, the lower 
confidence interval is greater than zero, and the ST sensitivity would be considered significantly less than the FO sensitivity.  
 
 

IVW-CLR-CS27- 400 ivWatch SmartTouch Sensor:  
Device Validation  for Infiltrated Tissues  
 
CONFIDENTIAL  35 of 58 
 
Figure 12. Exa mples of confidence intervals at various ST sensitivities, assuming FO sensitivity = 
96%.  
Quality Assurance  
As the research sponsor, ivWatch, LLC will continually monitor the research studies to ensure 
subject safety and data validity. Unlike multicenter s tudies, all aspects of the study are performed 
with ivWatch personnel facilitating the quality assurance process.  
The first component of the quality assurance program is ensuring the research personnel have the correct training to perform the studies. All study personnel (investigators, research staff, study monitors) will have the proper training (HIPAA and CITI) for conducting clinical trials prior to the start of the study. The subject screening will be performed by a registered nurse. 
The second component of the quality assurance program is the monitoring of studies to ensure the procedures outlined in this document are followed. This includes the procedures for data collection (ivWatch research system  operation), data storage, and data validation.  
The third component of the quality assurance program is monitoring the security of study data. As described in the data management section, study data stored in the database are password protected and restricted to authorized users. Any chang es to the database are tracked. The case 
report forms do not contain subject  identifiers. All paper health history forms will be stored in a 
locked filing cabinet . 
Monitoring Plan  
The Monitor will complete the initiation of the investigation site prior to beginning the study.  Based 
upon the length and complexity of this study, the Monitor will conduct periodic visits of the investigation site.  Minimally, the Monitor will visit the site prior to the closing out the study and complete the Monitoring Visit Checklist and Report using SF -1001020.  

IVW-CLR-CS27- 400 ivWatch SmartTouch Sensor:  
Device Validation  for Infiltrated Tissues  
 
CONFIDENTIAL  36 of 58 
Expected Outcomes of the Study  
The expected outcome of this study is an understanding of whether the ivWatch SmartTouch 
sensor will be as effective as the Model 400 for detecting early stage infiltrations.  
Publication Policy  
ivWatch will approve any publication released as a result of this research study. Results of the study may be published in various healthcare segments relating to vascular access , such as the Infusi on 
Nurses Society and Association for  Vascular Access.  
Duration of the Study  
Each study will last up to approximately 2 hours . The entire study is expected to require less than 
two month s to complete. 
Anticipated Problems  
Project timing and budgeting difficulties are not anticipated for this research p roject.  First, the 
study consists of approximately  115 participants (9 8 accepted case studies).  ivWatch is confident 
the necessary data can be collected from 98 subjects within 1-2 months . Second, the budget for 
this project is funded by ivWatch, LLC.   ivWatch will pay for costs specified in the clinical trial 
agreement.  
Ethics 
ivWatch, LLC  will follow ethical and regulatory guidelines while conducting this study. The 
investigators will not proceed with the study until the consent form has been signed b y each 
volunteer subject. Prior to obtaining informed consent signatures, the study will be verbally described to each volunteer and the investigators will address any outstanding questions or concerns. The investigators will receive the proper informed co nsent training prior to the study.  
Overall, the clinical investigation shall be conducted in accordance with the ethical principles 
that have their origin in the Declaration of Helsinki. Vulnerable populations will not be targeted for 
enrollment.  
Good Clinical Practice  
Good Clinical Practice (GCP) according to the ICH guidelines and ISO 14155 Clinical Investigation 
of Medical Devices will be followed for this study.  In addition, ivWatch clinical investigations follow 
ICH E6, and FDA 21CFR50,54, 56 and 812.   
IVW-CLR-CS27- 400 ivWatch SmartTouch Sensor:  
Device Validation  for Infiltrated Tissues  
 
CONFIDENTIAL  37 of 58 
 
Clinical Trial Insurance  
Insurance is provided to study subjects for medical expenses incurred  from bodily injury during 
clinical testing.  
Informed Consent Forms  
Please see the attached informed consent form.  
Deviations from the Protocol  
Investigators will notify the IRB of any deviation from the investigational plan/protocol to protect 
the life or physical well -being of a subject in an emergency as soon as possible, but not later than 
five (5) working days after the emergency occurred.  
Serious Adverse Events  / Device Deficiencies  
Serious adverse events and/or device deficiencies are not anticipated, as this general protocol 
has been followed with this device  and other research systems in several previous studies. All 
serious and unanticipated events will be reported as soon as possible, and no later than ten (10) 
working days after becoming aware of the event.  Other non -serious adverse events and device 
deficiencies will be recorded in the case report form.  
  
IVW-CLR-CS27- 400 ivWatch SmartTouch Sensor:  
Device Validation  for Infiltrated Tissues  
 
CONFIDENTIAL  38 of 58 
 Case Report Form  
1. General Study Informatio n 
 Case Report Form #:   
 Study Start Date (MM/DD/YYYY ):  
 
2. Inclusion Criteria   
  Signed consent   Subject 18 years or older   Health form approved  
 
3. General Subject  Information  
Gender:    Male   Female   
Age:    years  
 
4. Body Measurements   
 
 Weight :  lb 
 
Height:   
in 
 
 Systolic Blood 
Pressure :  mmHg  
 
Diastolic Blood 
Pressure:   mmHg  
  Forearm Circumference  
Left forearm:   mm 
Right forearm:   mm 
 
5. Skin Pigmentation  (Check one)  
 
 
Skin Type Score:    Fitzpatrick Skin Type:   
  Light    Medium    Dark  
 
6. Study Configuration  
 Left Site  Right Site  
Sensor  
(Select One Per Side)   Fiber Optic   SmartTouch  
  SmartTouch   Fiber Optic  
 
Site 
(Select One)   Hand   Forearm  
 
Infiltration Rate   cc/hr  
 
 
IRB #: Pro00032924  Principle Investigator: Jason Naramore  Revision Date: 3/12/2019  

IVW-CLR-CS27- 400 ivWatch SmartTouch Sensor:  
Device Validation  for Infiltrated Tissues  
 
CONFIDENTIAL  39 of 58 
CRF# _______ 
7. Pre-Study Information  
 Left Site  Right Site  
SmartTouchTM Sensor Serial No.   
Patient Cable Serial No.   
Extension Module Serial No.   
IPM Serial Number     
Fiber Optic Cable Serial No.   
Fiber Optic  Receptacle Lot No.   
Vein Viewer Photo (File ID)    
Pre-Insertion Photo (File ID)    
Ultrasound Images  
without C alipers  (Time)  (In-Plane ) (Out -Plane ) (In-Plane ) (Out -Plane ) 
Ultrasound Images  
with Calipers  (Time)  (In-Plane ) (Out -Plane ) (In-Plane ) (Out -Plane ) 
Catheter Depth  (mm) (In-Plane ) (Out -Plane ) (In-Plane ) (Out -Plane ) 
Post-Insertion Photo (File ID)    
Site Circumference (mm)   
 
      
IRB #: Pro00032924  Principle Investigator: Jason Naramore  Revision Date: 3/12/2019  
IVW-CLR-CS27- 400 ivWatch SmartTouch Sensor:  
Device Validation  for Infiltrated Tissues  
 
CONFIDENTIAL  40 of 58 
CRF# _______  
8. Study Information  
 Left Site  Right Site  
IPM Start Time  (HH:MM:SS)    
Staff Initials  (Verify correct pump rate)    
Pump Start Time  (HH:MM:SS)    
Pump Stop Time  (HH:MM:SS)    
Total Volume Infused  (mL)   
IPM Stop Time  (HH:MM:SS)    
 
9. Post-Study Information   
 Left Site   Right Site  
Site Circumference  (mm)   
Dressed Site Photo (File ID)    
Vein Viewer (File ID )   
Ultrasound Images  
without Calipers (Time)  (In-Plane ) (Out -Plane ) (In-Plane ) (Out -Plane ) 
Ultrasound Images  
with Calipers (Time)  (In-Plane ) (Out -Plane ) (In-Plane ) (Out -Plane ) 
Catheter Depth (mm) (In-Plane ) (Out -Plane ) (In-Plane ) (Out -Plane ) 
Catheter Displacement (mm)   
Bare Site Photo (File ID)    
 
 
 
IRB #: Pro00032924  Principle Investigator: Jason Naramore  Revision Date: 3/12/2019  
IVW-CLR-CS27- 400 ivWatch SmartTouch Sensor:  
Device Validation  for Infiltrated Tissues  
 
CONFIDENTIAL  41 of 58 
CRF# _______  
10. Miscellaneous Notes   
Are there any additional comments related to the case study?  
Please include comments below.  
  Yes  No 
 N/A 
 
11. Device Deficiencies / Malfunctions   
Did the investigation device not perform as expected by the 
intended use when used per the instructions and the protocol?  
 
Could this deficiency/malfunction have led to an 
adverse event?  
 
If yes to either question, please explain:  
  Yes  No 
 N/A  Yes  No 
 N/A 
 
12. Adverse Events   
Did the patient experience any unexpected harm associated  
with the ivWatch Model 400 device or the research protocol?  
 
Is this event reportable?  
 
If yes to either question, please explain:  
 
  Yes  No 
 N/A  Yes  No 
 N/A 
 
13. Authorization   
I certify that to the best of my  
knowledge, the information  
contained in this form is true  
and correct.     
Signature of Investigator   Date  
   
Printed  Name of Investigator    
IRB #: Pro00032924  Principle Investigator: Jason Naramore  Revision Date: 3/12/2019  
IVW-CLR-CS27- 400 ivWatch SmartTouch Sensor:  
Device Validation  for Infiltrated Tissues  
 
CONFIDENTIAL  42 of 58 
Pre-Screening  Form  
Name: (Last)     (First)      (Middle Initial)    
Date of Birth: (MM/DD/YYYY)     
Phone:      Email:     
 
Medical Questions  Yes*  No 
1. Do you have any allergies?    
2. Are you currently participating in any other medical studies?    
3. Do you have a history of fainting when needles are used on you?    
4. Are you taking any medications?    
5. Have you been hospitalized in the past 14 days?    
6. Have you been sick or had an infection in the past 14 days?    
7. Have you received IV therapy in the past 14 days?    
8. Do you have tattoos covering more than half of your inner forearms or back of your hands?    
9. Do you have significant scar tissue  on your inner  forearms or back of your hands ?   
10. Do you have an absence of sensation in your arms?    
11. (For females only) Are you currently pregnant?   N/A 
*If yes to any of the above, please explain:  
 
  
N/A 
 
 
 
**Eligible   Ineligible   ivWatch Staff Signature  _____________________________  Date  _____________  
 
**If â€œyesâ€ is checked for any of the shaded â€œYesâ€ boxes  and there isnâ€™t  acceptable reasoning , the subject is ineligible. If 
you are unsure about the subjectâ€™s eligibility, consult the physician/nurse on staff to determine eligibility.  
 
Date  
 
Time  
 
Consulted physician /nurse  
 Notes from consultation:  
 
  
 
  
N/A Medical History  
Condition  Yes*  No Condition  Yes*  No 
Bleeding Disorder    Immune Deficiency Disorders    
Cardiopulmonary Disorders    Lymphedema    
Clotting Disorders    Radiation/Chemotherapy    
Currently anemic     Seizures/Epilepsy     
Hepatitis     Stroke    
HIV/Aids    Tuberculosis     
*If yes to any shaded areas above, please explain:  
  
 
N/A 
If you have any other medical conditions we should be aware  of, please explain below.  
If yes, please explain:  
  
 
N/A 
IVW-CLR-CS27- 400 ivWatch SmartTouch Sensor:  
Device Validation  for Infiltrated Tissues  
 
CONFIDENTIAL  43 of 58 
 Health History  Form  
Name: (Last)     (First)      (Middle Initial)    
Date of Birth: (MM/DD/YYYY)     
Address: (Street)      
(City)    (State)    (Zip)       
Phone:      Email:     
 
Medical Questions  Yes*  No 
1. Do you have any allergies?    
2. Are you currently participating in any other medical studies?    
3. Do you have a history of fainting when needles are used on you?    
4. Are you taking any medications?    
5. Have you been hospitalized in the past 14 days?    
6. Have you been sick or had an infection in the past 14 days?    
7. Have you received IV therapy in the past 14 days?    
8. Do you have tattoos covering more than half of  your inner forearms or back of your hands ?   
9. Do you have significant scar tissue on your inner forearms or back of your hands?    
10. Do you have an absence of sensation in your arms?    
11. (For females only) Are you currently pregnant?   N/A 
*If yes to any of the above, please explain:  
 
N/A 
 
 
Temperature:  __________ ËšF  
 
**Eligible   Ineligible   ivWatch Staff Signature  _______________ ______________ Date __________ ___ 
 Medical History  
Condition  Yes*  No Condition  Yes*  No 
Bleeding Disorder    Immune Deficiency Disorders    
Cardiopulmonary Disorders    Lymphedema    
Clotting Disorders    Radiation/Chemotherapy    
Currently anemic     Seizures/Epilepsy     
Hepatitis     Stroke    
HIV/Aids    Tuberculosis     
*If yes to above, please explain:  
 
 
N/A 
If you have any other medical conditions we should be aware  of, please explain below.  
If yes, please explain:  
 
N/A 
**If â€œyesâ€ is checked for any of the shaded â€œYesâ€ boxes  and there isnâ€™t  acceptable reasoning , the subject is ineligible. If 
you are unsure about the subjectâ€™s eligibility, consult the physician/nurse on staff to determine eligibility.  
 
Date  
 
Time  
 
Consulted physician /nurse  
 Notes from consultation:  
 
  
 
  
N/A 
IVW-CLR-CS27- 400 ivWatch SmartTouch Sensor:  
Device Validation  for Infiltrated Tissues  
 
CONFIDENTIAL  44 of 58 
Skin Pigmentation Worksheet  
Skin Pigmentation Worksheet  
CRF Number: _________  
Reaction to Sun Exposure  
Score  0 1 2 3 4 
What happens 
when you stay in 
the sun too long?  Painful 
redness, 
blistering, 
peeling  Blistering 
followed by 
peeling  Burns 
sometimes 
followed by 
peeling  Rare burns  Never had 
burns 
To what degree 
do you turn 
brown?  Hardly or not 
at all  Light color 
tan Reasonable 
tan Tan very 
easy Turn dark 
brown 
quickly  
Do you turn brown 
within several 
hours after sun 
exposure?  Never  Seldom  Sometimes  Often  Always  
How does your 
face react to the 
sun?  Very 
sensitive  Sensitive  Normal  Very 
resistant  Never had a 
problem  
 
Total Score for Reaction to Sun Exposure: ___________   
 
  Tanning Habits  
Score  0 1 2 3 4 
When did you last 
expose your body 
to sun (or artificial 
sunlamp/tanning 
cream)?  More than 3 
months ago  2-3 months 
ago 1-2 months 
ago Less than a 
month ago  Less than 2 
weeks ago  
Did you expose 
the area to be 
treated to the 
sun?  Never  Hardly ever  Sometimes  Often  Always  
 
Total Score for Tanning Habits: ___________   
IVW-CLR-CS27- 400 ivWatch SmartTouch Sensor:  
Device Validation  for Infiltrated Tissues  
 
CONFIDENTIAL  45 of 58 
 
Skin Pigmentation Worksheet  
CRF Number: _________  
Genetic Disposition  
Score  0 1 2 3 4 
What is the color 
of your eyes?  Light Blue, 
Gray, Green  Blue, Gray  
or Green  Blue Dark Brown  Brownish 
Black  
What is the natural 
color of your hair?  Sandy Red Blond  Chestnut/  
Dark Blond  Dark Brown  Black  
What is the color 
of your skin (non-
exposed areas)?  Reddish  Very Pale  Pale with 
Beige tint  Light Brown  Dark Brown  
Do you have 
freckles on 
unexposed areas?  Many Several  Few Incidental  None  
 
Total Score for Genetic Disposition: ___________  
 
Add up the total scores for each of the three sections for your Skin Type Score.  
Skin Type Score  Fitzpatrick Skin Type  
0-7 I 
8-16 II 
17-25 III 
26-30 IV 
over 30  V-VI 
 
 
My Skin Score    My Skin Type   
 
  
IVW-CLR-CS27- 400 ivWatch SmartTouch Sensor:  
Device Validation  for Infiltrated Tissues  
 
CONFIDENTIAL  46 of 58 
Pre-Study Checklist  
CRF#: ________  
Step  Role Status  Task 
1.  Subject   Sign in at the reception desk and show identification.  
2.  Research 
Assistant   Subject taken to private screening room.  
3.  Research 
Assistant   Provide informed consent form with description of the study.  
4.  Research 
Assistant   Discuss study and ask if the subject has questions regarding the 
study and/or their rights as a participant.  
5.  Subject   Review and either sign consent form or opt -out of study.  
6.  Research 
subject   Take subject to health screening room.  
7.  Nurse   Provide health history form to subject.  
8.  Subject   Complete health history form.  
9.  
Nurse   Ask subject if they have  questions regarding the health history 
form.  Measure body temperature of the subject and record at 
the bottom of the form.  
10.  
Nurse   Review the completed health history form. If a section is marked 
â€œyes,â€ confirm the subject has provided an explanation. If  
necessary, consult with the physician on staff for sections marked 
as â€œyesâ€ and determine the subjectâ€™s eligibility.  
11.  Nurse   If health history form is accepted, complete Sections 1 -3 of the 
Case Report Form. 
12.  
Nurse   Perform health screening of the subject to measure weight, 
height, blood pressure, and forearm circumference. Record 
measurements in Section 4 of the Case Report Form. 
13.  
Nurse   Work through the Subject Pigmentation Worksheet with the 
subject. Calculate the final score for the subject and  record in 
Section 5 of the Case Report Form.  
14.  
Nurse   Use personal judgement to determine the skin tone of the subject 
and record in Section 5 of the Case Report Form. 
15.  
Nurse   If the subject has passed  the health history form and Sections 1 -6 
are completed in the Case Report Form , take subject to the test 
area.  
 
 
 
IVW-CLR-CS27- 400 ivWatch SmartTouch Sensor:  
Device Validation  for Infiltrated Tissues  
 
CONFIDENTIAL  47 of 58 
Data Collection Checklist  
CRF#: ________  
Step  Role Status  Task 
1 Research 
Assistant   Subject taken to test room.  Ensure subject comfort.  
2 Nurse   Nurse and ultrasound tech to perform hand hygiene. Apply latex -free 
gloves.  
3 Research 
Assistant   Review Sections 1 -6 of the case report form.  
4 Research 
Assistant   Record the serial /lot numbers of the ivWatch equipment in Section 7 
of the case report form.  
5 Nurse   On the Fiber Optic IPM, set up the run and verify the cable is 
functioning properly. The IPM should show the placement screen.  
Prepare Site on Left Arm  
6 Nurse   If necessary, shave the site location.  
7 Research 
Assistant   Photograph VeinViewer illumination at site. Record File ID of 
VeinViewer P hotograph in Section 7 of case report form . 
8 Research 
Assistant   Photograph bare site. Record  File ID of  Pre-Insertion Photograph in 
Section 7 of the case report form.  
9 Nurse   Clean selected area on subject with CHG Swabstick for 30 seconds 
and allow to air dry for 30 seconds.  
10 Nurse   Place catheter tip next to a vein typically used for IV therapy . If 
needed, use ultrasound during placement. Discard needle in sharps 
container.   
11 US Tech   Record post-insertion  ultrasound images of injection site.   
â€¢ Capture in -plane ultrasound image of catheter and measure 
depth of catheter tip.  
â€¢ Capture out -of-plane ultrasound image of catheter  and measure 
depth of catheter tip.  
â€¢ Record ultrasound file IDs (time) and catheter depth in section 7 
of the case report form.  If images are in the same minute , label the 
second image with â€œaâ€.  
â€¢ Remove ultrasound gel from site using gauze and clean area with 
two alcohol wipes.  
12 Nurse   Connect IV Tubing to Catheter  
â€¢ Remove air from catheter hub using normal saline . 
â€¢ Connect IV tubing to catheter.  
â€¢ Dry area around catheter using gauze.  
â€¢ Place a piece of tape over catheter to hold in place.  
13 Nurse   The configuration is not over  dressing . 
a. Apply occlusive dressing over injection site.  
b. Adhere ivWatch sensor on the same side of the vein as the 
catheter while using spare catheter for placement.  
c. Verify sensor is approximately 5 mm from the catheter.  
14 Nurse   Perform cable management and secure senso r cable to IV tubing 
using medical tape.  
15 Nurse   Check that the sensor is connected to the corresponding ivWatch 
patient monitor (IPM).  
IVW-CLR-CS27- 400 ivWatch SmartTouch Sensor:  
Device Validation  for Infiltrated Tissues  
 
CONFIDENTIAL  48 of 58 
16 Research 
Assistant   Photograph monitoring site. Record File ID of Post -Insertion 
Photograph in Section 7  of case report form.  
Prepare Site on Right  Arm 
17 Research 
Assistant   Photograph VeinViewer illumination at site. Record File ID of 
VeinViewer P hotograph in Section 7 of case report form . 
18 Research 
Assistant   Photograph bare site. Record File ID of Pre-Insertion Photograph in 
Section 7 of the case report form.  
19 Nurse   Clean selected area on subject with CHG Swabstick for 30 seconds 
and allow to air dry for 30 seconds.  
20 Nurse   Place catheter tip next to a vein typically used for IV therapy.  If 
needed, use ultrasound to place the catheter . Discard needle in 
sharps container.  
21 US Tech   Record post -insertion ultrasound images of injection site.  
â€¢ Capture in -plane ultrasound image of catheter and m easure 
depth of catheter tip.  
â€¢ Capture out -of-plane ultrasound image of catheter  and m easure 
depth of catheter tip.  
â€¢ Record ultrasound file IDs and catheter depth in section 7 of the 
case report form.  If the images are in the same minute, label the 
second image with â€œaâ€.  
â€¢ Remove ultrasound gel from site using  gauze and clean area with  
two alcohol wipes.   
22 Nurse   Connect IV Tubing to Catheter  
â€¢ Remove air from catheter hub using normal saline . 
â€¢ Connect IV tubing to catheter . 
â€¢ Dry area  around catheter using gauze.  
â€¢ Place a piece of tape over catheter to hold in place.  
23 Nurse   The configuration is not over  dressing . 
a. Apply occlusive dressing over injection site.  
b. Adhere ivWatch sensor on the same side of the vein as the catheter while  using the spare catheter for placement.  
c. Verify sensor is approximately 5 mm from the catheter.   
24 Nurse   Perform cable management and secure sensor cable to IV tubing 
using medical tape.  
25 Nurse   Check that the sensor is connected to the corresponding ivWatch 
patient monitor (IPM).  
26 Research 
Assistant   Photograph monitoring site. Record File ID of Post -Insertion 
Photograph in Section 7  of case report form.  
27 Nurse   Clean ultrasound probe by wiping thoroughly with Sani -Cloth Wipe.  
  
IVW-CLR-CS27- 400 ivWatch SmartTouch Sensor:  
Device Validation  for Infiltrated Tissues  
 
CONFIDENTIAL  49 of 58 
Data Collection  
28 Nurse   Site Circumference Measurement. Mark a line  on the dressing 
indicating where to place the measuring tape , such that the 
circumference is measured at the approximate location of the 
catheter tip . Complete this on both arms. Record Site Circumference s 
in Section 7 of case report form.  
29 Nurse   Start data acquisition on IPMs. Using the digital clock, 
record acquisition start time in Section 8 of case report 
form.  t = 0 min  
30 Nurse   Start IV pumps. Record start times in Section 8 of case 
report form.  t = 5 min  
31 Nurse   Record stop times in Section 8 of case report form.  10 mL infiltrated  
32 Nurse   Stop data acquisition on IPM. Record acquisition stop 
time ( digital clock) in Section 8 of case report form.  5 minutes after 
both pumps 
stopped  
33 Nurse   Measure  circumference of the subcutaneous injection site s on both 
arms using previous markings. Record Site C ircumferences  in Section 
9 of the case report form.  
34 Research 
Assistant   Begin data transfer  on the IPMs.  
Left Arm Po st Study Assessment  
35 Research 
Assistant   Photograph  monitoring  site. Record  File ID of Dressed Site Photograph 
in Section 9 of case report form.  
36 Nurse   Remove occlusive dressing and ivWatch sensor from site.  Mark 
location of  sensor head . 
37 Research 
Assistant   Photograph VeinViewer illumination at site. Record File ID of 
VeinViewer P hotograph in Section 9 of case report form . 
38 US Tech   Record ultrasound images of injection site after infiltration complete.  
â€¢ Capture in -plane ultrasound image of catheter and measure 
catheter depth.  
â€¢ Capture out -of-plane ultrasound image of catheter  and measure 
catheter depth . 
â€¢ Record ultrasound file IDs and catheter depth in section 9 of the 
case report form.  If the images are in the same minute, label the 
second image with  â€œaâ€. 
â€¢ Remove ultrasound gel from site using gauze.  
â€¢ Measure displacement between catheter tip and sensor . Record 
in Section 9 of case report form . 
39 Nurse   Remove catheter. Apply light pressure until bleeding stops. Try not to 
displace infiltrated fluid.  
40 Research 
Assistant   Photograph bare  site for record of skin integrity. Record File ID of Bare 
Site Photograph in  Section 9 of case report form . 
41 Nurse   Apply adhesive bandage to site.  
Right Arm Post Study Assessment  
42 Research 
Assistant   Photograph  monitoring  site. Record  File ID of Dressed Site Photograph 
in Section 9 of case report form.  
43 Nurse   Remove occlus ive dressing and ivWatch sensor  from site.  Mark 
location of sensor head . 
44 Research 
Assistant   Photograph  VeinViewer illumination at site. Record File ID of 
VeinViewer P hotograph in Section 9 of case report form.  
IVW-CLR-CS27- 400 ivWatch SmartTouch Sensor:  
Device Validation  for Infiltrated Tissues  
 
CONFIDENTIAL  50 of 58 
45 US Tech   Record ultrasound images of injection site after infiltration complete.  
â€¢ Capture in -plane ultrasound image of catheter and measure 
cathe ter depth.  
â€¢ Capture out -of-plane ultrasound image  and measure catheter 
depth . 
â€¢ Record ultrasound file IDs and catheter depth in section 9 of the 
case report form.  If the images are in the same minute, label the 
second image with â€œaâ€.  
â€¢ Remove ultrasound gel fr om site using gauze . 
â€¢ Measure displacement between catheter tip and sensor and 
record in Section 9 of case report form . 
46 Nurse   Remove catheter. Apply light pressure until bleeding stops. Try not to 
displace infiltrated fluid.  
47 Research 
Assistant   Photograph bare  site for record of skin integrity. Record File ID of Bare 
Site Photograph in Section 9 of case report form . 
48 Nurse   Apply adhesive bandage to site.  
49 Nurse   Clean ultrasound probe by wiping with Sani -Cloth Wipe.  
Study Completion  
50 Research 
Assistant   Complete Sections 10-13 in case report form.  
51 Research 
Assistant   Take subject to front reception desk and provide study participation 
payment. Provide a copy of the patientâ€™s ICF  should the y have 
questions after leaving.  
52 Subject   Sign and date the check -out sheet to verify receipt of payment. The 
subject leaves.  
53 Research 
Assistant   Remove tape connecting IV tubing and sensor cable. Dispose of the 
IV tubing. Clean the ivWatch sensor with hospital -grade disinfectant 
wipes. Bundle the cable and store on the IV pole.  
54 Research 
Assistant   Clean the test area.   
55 Research 
Assistant   Transfer the following to the network server:  
1. ivWatch Data (via USB drive)  
2. Ultrasound Images (via USB drive)  
3. Camera Images  
56 Research 
Assistant   Store paperwork (case report form  and checklists ) in manila folder. 
Provide paperwork containing private health information to HIPAA 
officer for separate and secure storage.  
IVW-CLR-CS27- 400 ivWatch SmartTouch Sensor:  
Device Validation  for Infiltrated Tissues  
 
CONFIDENTIAL  51 of 58 
FDA Clearance Letters for ivWatch Model 400  

IVW-CLR-CS27- 400 ivWatch SmartTouch Sensor:  
Device Validation  for Infiltrated Tissues  
 
CONFIDENTIAL  52 of 58 
 
 

IVW-CLR-CS27- 400 ivWatch SmartTouch Sensor:  
Device Validation  for Infiltrated Tissues  
 
CONFIDENTIAL  53 of 58 
 

IVW-CLR-CS27- 400 ivWatch SmartTouch Sensor:  
Device Validation  for Infiltrated Tissues  
 
CONFIDENTIAL  54 of 58 
  

IVW-CLR-CS27- 400 ivWatch SmartTouch Sensor:  
Device Validation  for Infiltrated Tissues  
 
CONFIDENTIAL  55 of 58 
 Investigator Signatures 
Example [ I certify that I am knowledg eable about the regulations and policies governing research 
with human subjects. I have reviewed this document  and agree to conduct the study in 
accordance with the approved protocol. ] 
 
 
Principal Investigato r Name:  William J. Naramore  
Signature:   
Date:   
 
 
Investigator  Name:  Susan Brown, MSN, MSED, BA , VA-BC 
Signature:   
Date:   
 
 
Investigator  Name:  Gregory J. Schears, M.D.  
Signature:   
Date:   
 
 
Investigator  Name:  Marisa A. Cole  
Signature:   
Date:   
 
 
 
 
  
IVW-CLR-CS27- 400 ivWatch SmartTouch Sensor:  
Device Validation  for Infiltrated Tissues  
 
CONFIDENTIAL  56 of 58 
 Statistical Monte Carlo Analysis  
clear variables; 
close all; 
clc; 
  % Parameters of the Monte Carlo Simulation simulation.number_of_trials = 1000000; simulation.alternative_hypothesis_sensitivity = 0.90;   
% Perform the Monte Carlo Simulation (method included below) 
results = simulate_study2(simulation); 
  % Generate figure of simulated distributions figure; h(1) = bar(results.bins, results.null_sensitivities_bins/max(results.null_sensitivities_bins)); hold on; 
h(2) = bar(results.bins, 
results.alternative_sensitivities_bins/max(results.alternative_sensitivities_bins)); 
set(h(2),'FaceColor', 'r'); 
set(get(h(1),'Children'),'EdgeAlpha',0) set(get(h(2),'Children'),'EdgeAlpha',0) set(get(h(1),'Children'),'FaceAlpha',0.5) set(get(h(2),'Children'),'FaceAlpha',0.5) xlim([0 110]) xlabel('Infiltration Sensitivity (%)') h_legend = legend('Null Hypothesis', 'Alternative Hypothesis'); 
set(h_legend,'Location', 'NorthWest') 
children = get(h_legend,'Children'); alt_box = get(children(1),'Children'); null_box = get(children(3),'Children'); set(alt_box,'FaceAlpha',0.5); set(null_box,'FaceAlpha',0.5); set(alt_box,'EdgeAlpha',0); 
set(null_box,'EdgeAlpha',0); 
set(h_legend,'EdgeColor',[1 1 1]); hold on; 
plot(results.threshold*[1 1], [0,1],'r-' ) 
  % Printe statistical metrics to MATLAB console fprintf(1,'Threshold: %f (%f H0 cases below this threhsold)\ r', results.threshold, 
results.confidence); fprintf(1,'Statistical Power (1- Beta): %f\ r', results.power); 
fprintf(1,'Alpha: %f (one- sided)\r', results.alpha); 
fprintf(1,'Beta: %f \r',results.beta); 
fprintf(1,'Mean Null: %f', results.mean_null);   % Generate plot showing statistical power as a function of the sensitivity  % of the alternative hypothesis alternative_hypotheses = [0.25:0.01:1]; h = waitbar(0,'Please be patient Jason' ); 
for i=1:length(alternative_hypotheses) 
    simulation.alternative_hypothesis_sensitivity = alternative_hypotheses(i);     results = simulate_study2(simulation);     powers(i) = results.power;     waitbar(i/length(alternative_hypotheses),h); end close(h); 
figure; 
plot(alternative_hypotheses*100,100* powers,'r-' ); 
xlabel('Device Sensitivity (Alternative Hypothesis)'); ylabel('Statistical Power (%)'); title('70 PIV Site Study') grid   % Save figure %gtb_save_figure(figure(1),'MonteCarloAnalysis') %gtb_save_figure(figure(2),'StatisticalPowerAnalysis') 
  
IVW-CLR-CS27- 400 ivWatch SmartTouch Sensor:  
Device Validation  for Infiltrated Tissues  
 
CONFIDENTIAL  57 of 58 
 
function [results] = simulate_study2(simulation) 
  
% Load study simulation details number_of_trials = simulation.number_of_trials; number_of_subjects = 90; % Load the alternative hypothesis sensitivity (predicted sensitivity of % ivWatch device) alternative_hypothesis_sensitivity = simulation.alternative_hypothesis_sensitivity;   % The volume limit  Vlim = 10;   % List of rates  
rates = [5; 25; 50; 75; 100; 125; 150];   % Detection by the perfect clinician is uniformly distirbuted between 0 and % 60 minutes   
for i=1:number_of_trials 
    % Detection times uniformly distributed between 0 and 60 minutes     detection_matrix_null = 60*rand(7,14);       % The perfect clinician detects the infiltration if     % (detection_matrix_null)<Vlim/R*60     sensitivity_matrix_null = detection_matrix_null < Vlim./repmat(rates,1,14)*60;   
    % Sensitivity for the perfect clinician for this particular trial 
    null_sensitivities(i) = 
sum(sensitivity_matrix_null(:))/length(sensitivity_matrix_null(:))*100; 
      % Generate matrix with uniformly distributed numbers between 0 and 1.     sensitivity_matrix_alt = rand(7,14);          % Sensitivity for the ivWatch device for this particular trial 
    alternative_sensitivi ties(i) = 
sum(sensitivity_matrix_alt(:)<alternative_hypothesis_sensitivity) / 
length(sensitivity_matrix_alt(:))*100; 
end   
% Bin the results bins = (1:number_of_subjects)/number_of_subjects*100; null_sensitivities_bins = hist(null_sensitivities,bins); alternative_sensitivities_bins = hist(alternative_sensitivities,bins); 
  
% Figure out a threshold where > 95% of the clinician sensitivities are % less than this threshold null_cumsum = cumsum(null_sensitivities_bins)./ sum(null_sensitivities_bins); pos = find(null_cumsum > 0.95); threshold = (bins(pos(1))+bins(pos(1)+1))/2;   % Calculate statistical metrics power = sum(alternative_sensitivities_bins(bins > threshold))/sum(alternative_sensitivities_bins);  
alpha = sum(null_sensitivities_bins(bins > threshold))/sum(null_sensitivities_bins); beta = sum(alternative_sensitivities_bins(bins < threshold))/sum(alternative_sensitivities_bins);   % Output results results.threshold = threshold; results.confidence = 1- alpha; 
results.power = power; results.alpha = alpha; results.beta = beta; results.bins = bins; results.null_sensitivities_bins = null_sensitivities_bins; results.alternative_sensitivities_bins = alternative_sensitivities_bins; results.mean_null = mean(null_sensitivities);  
  
IVW-CLR-CS27- 400 ivWatch SmartTouch Sensor:  
Device Validation  for Infiltrated Tissues  
 
CONFIDENTIAL  58 of 58 
 Bibliography  
[1]  E. M. Kagel and G. M. Rayan, "Intravenous catheter complications in the hand and forearm," 
J Trauma -Injury Infection & Crit Care, vol. 56, no. 1, pp. 123- 127, Jan 2004.  
[2] R. E. Helm, J. D. Klausner, J. D. Klemperer, L. M. Flint and E. Huang, â€œAccepted but 
unacceptable: peripheral IV catheter failure,â€ J Infus Nurs , vol. 38, no. 3, pp. 189- 203, May 
2015.  
[3]  C. M. Rickard, J. Webster, M. C. Wallis, N. Marsh, M. R. McGrail, V. French, L. Foster, P. 
Gallagher, J. R. Gowardman, L. Zhang, A. McClymont and M. Whitby, "Routine versus 
clinically indicated replacement of peripheral intravenous catheters: a randomised 
controlled equivalence trial," Lancet, vol. 380, pp. 1066- 1074, 2012.  
[4]  D. T. Gault, "Extravasation injuries," Br J Plast Surgery, vol. 46, no. 2, pp. 91 -96, Mar 1993.  
[5]  S. Phelps and R. A. Helms, "Risk factors affecting infiltration of periphera l venous lines in 
infants," J Pediatr, vol. 111, no. 3, pp. 384 -389, Sep 1987.  
[6]  S. Masoorli, "Infusion therapy lawsuits," J. Intravenous Nursing, vol. 18, pp. 88 -91, 1995.  
[7]  J. B. B. a. C. L. Jacobs, "Contrast media reactions and extravasation: Relationship to 
intravenous injection rates," Radiol., vol. 176, pp. 411- 416, 1998.  
[8] M. C. Wallis, M. McGrail, J. Webster, N. Marsh, J. Gowardman, E. G. Playford, and C. M. 
Rickard, â€œRisk factors for peripheral intravenous catheter failure: a multivariate analysis of 
data fro m a randomized controlled trial,â€ Infect Control Hosp Epidemiol , vol. 35, no. 1, pp. 
63-68, Jan 2014.  
[9]  J. Pettit, "Assessment of Infant with a Peripheral Intravenous Device," Adv Neonatal Care, vol. 
3, no. 5, 2003.  
[10]  Infusion Nurses Society, in Infusion Nursing: An Evidence -Based Approach , St. Louis, Missori, 
Elsevier, 2010, pp. 516- 517. 
 